CLINICAL STUDY PROTOCOL

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

IND Number: 125589
EudraCT Number: 2015-004024-54
Clinical Trials.gov Identifier: NCT02607930

Indication: HIV-1 Infection


Gilead Study Clinical Program Manager: Name: Hal Martin, MD, MPH
Telephone: PPD
Fax: PPD

Gilead Medical Monitor: Name: Hal Martin, MD, MPH
Telephone: PPD
Fax: PPD
Pager: PPD

Protocol Version/Date: Original: 21 October 2015
Amendment 1: 19 February 2016

CONFIDENTIALITY STATEMENT

The information contained in this document, particularly unpublished data, is the property or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered.
TABLE OF CONTENTS

1. INTRODUCTION .............................................................................................................................................. 16
   1.1. Background .................................................................................................................................................. 16
   1.2. GS-9883 .................................................................................................................................................... 17
       1.2.1. General Information .......................................................................................................................... 17
       1.2.2. Preclinical Pharmacology and Toxicology ....................................................................................... 17
       1.2.3. Clinical Trials of GS-9883 ................................................................................................................... 19
   1.3. Information about Emtricitabine (Emtriva®, FTC) ................................................................................. 28
   1.4. Information about Tenofovir alafenamide (TAF, GS-7340) ................................................................. 28
       1.4.1. Clinical Trials of Single Agent Tenofovir alafenamide (TAF, GS-7340) or Fixed Dose Combination
              emtricitabine/tenofovir alafenamide (FTC/TAF) .............................................................................. 29
       1.4.2. Clinical Trials of FTC/TAF as part of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
              (E/C/F/TAF) ........................................................................................................................................ 30
   1.5. Information about GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) ......................... 32
       1.5.1. GS-US-141-1233: Study of the Relative Bioavailability of GS-9883, FTC, and TAF between
              GS-9883/F/TAF and GS-9883 + F/TAF ................................................................................................. 32
   1.6. Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC Truumeq®) ............................... 33
   1.7. Rationale for this Study ................................................................................................................................. 33
   1.8. Risk/Benefit Assessment for the Study ...................................................................................................... 34
   1.9. Rationale for Dose Selection ...................................................................................................................... 35
   1.10. Compliance ............................................................................................................................................... 36

2. OBJECTIVES ..................................................................................................................................................... 37

3. STUDY DESIGN .................................................................................................................................................. 38
   3.1. Endpoints .................................................................................................................................................... 38
   3.2. Study Design .............................................................................................................................................. 38
   3.3. Study Treatments ...................................................................................................................................... 38
   3.4. Duration of Treatment ................................................................................................................................. 39
   3.5. Biomarker Testing .................................................................................................................................... 39
       3.5.1. Biomarker Samples for Optional Pharmacogenomic Research ...................................................... 39
       3.5.2. Additional Sample Storage .................................................................................................................. 40

4. SUBJECT POPULATION .................................................................................................................................. 41
   4.1. Number of Subjects and Subject Selection ............................................................................................. 41
   4.2. Inclusion Criteria ..................................................................................................................................... 41
   4.3. Exclusion Criteria ................................................................................................................................... 42

5. INVESTIGATIONAL MEDICINAL PRODUCTS .............................................................................................. 45
   5.1. Randomization, Blinding and Treatment Codes .................................................................................... 45
       5.1.1. Procedures for Breaking Treatment Codes ..................................................................................... 45
   5.2. Description and Handling ........................................................................................................................ 46
       5.2.1. Formulation ...................................................................................................................................... 46
       5.2.2. Packaging and Labeling .................................................................................................................. 46

CONFIDENTIAL  Page 2  19 February 2016
5.2.3. Storage and Handling ..........................................................47
5.3. Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide and Abacavir/Dolutegravir/Lamivudine ..........................................................47
5.4. Prior and Concomitant Medications ...........................................48
5.5. Accountability for Investigational Medicinal Product (IMP) .................49
5.5.1. Investigational Medicinal Product Return or Disposal ......................49
6. STUDY PROCEDURES ........................................................................................................50
6.1. Subject Enrollment and Treatment Assignment .................................50
6.2. Pretreatment Assessments ..............................................................50
6.2.1. Screening Visit ...........................................................................50
6.2.2. Day 1 Assessments .................................................................52
6.3. Randomization ..................................................................................54
6.4. Treatment Assessments (Week 4 - 96) ...............................................54
6.5. Treatment Assessments (Post Week 96 until the Unblinding Visit) ........57
6.5.1. Post Week 96 Assessments .......................................................57
6.5.2. Unblinding Visit ...........................................................................58
6.6. Post-treatment Assessments .............................................................60
6.6.1. Early Study Drugs Discontinuation Assessments .........................60
6.6.2. 30 Day Follow Up ......................................................................61
6.7. Criteria for Discontinuation of Study Treatment .................................62
6.8. Bone Mineral Density Evaluations ..................................................63
6.9. Other Evaluations ...........................................................................63
6.9.1. Markers of Renal Tubular Function ...........................................63
6.9.2. Markers of Inflammation and Immune Activation .......................63
6.9.3. Markers of Platelet Function ......................................................63
6.10. Blood and Urine Storage .................................................................63
6.11. Assessments for Premature Discontinuation from Study ..................64
6.12. End of Study ..................................................................................64
6.13. Post Study Care .............................................................................64
6.14. Virologic Failure ............................................................................64
6.14.1. Management of Virologic Rebound ...........................................64
6.14.2. Subjects with HIV-1 RNA ≥ 50 copies/mL at Study Discontinuation, Week 48 or Week 96 .................................66
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ........................................................................67
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ........................................67
7.1.1. Adverse Events ..........................................................................67
7.1.2. Serious Adverse Events ..............................................................67
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events ........................................68
7.2. Assessment of Adverse Events and Serious Adverse Events ...............68
7.2.1. Assessment of Causality for Study Drugs and Procedures ..............68
7.2.2. Assessment of Severity ............................................................69
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead ........................................................................................................69
7.3.1. Adverse Events ..........................................................................69
7.3.2. Serious Adverse Events ..............................................................70
7.4. Gilead Reporting Requirements ........................................................71
7.5. Toxicity Management .....................................................................71
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event ..............71
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event .........................72
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event .........................72
7.5.4. Management of Possible Abacavir Hypersensitivity Reaction ..........72
7.5.5. Management of Potential Hepatobiliary Toxicity ................................................................. 73
7.5.6. On-Treatment Hepatitis C Management ............................................................................. 73

7.6. Special Situations Reports ........................................................................................................... 74
  7.6.1. Definitions of Special Situations .......................................................................................... 74
  7.6.2. Instructions for Reporting Special Situations ................................................................. 74

8. STATISTICAL CONSIDERATIONS ................................................................................................. 76
  8.1. Analysis Objectives and Endpoints ......................................................................................... 76
    8.1.1. Analysis Objectives ........................................................................................................... 76
    8.1.2. Primary Endpoint ............................................................................................................. 76
    8.1.3. Secondary Endpoint ......................................................................................................... 76
  8.2. Analysis Conventions .................................................................................................................. 76
    8.2.1. Analysis Sets ..................................................................................................................... 76
  8.3. Data Handling Conventions ........................................................................................................ 78
  8.4. Demographic Data and Baseline Characteristics ...................................................................... 79
  8.5. Efficacy Analysis ......................................................................................................................... 79
    8.5.1. Primary Analysis ............................................................................................................... 79
    8.5.2. Secondary Analyses ........................................................................................................... 80
  8.6. Safety Analysis .......................................................................................................................... 81
    8.6.1. Extent of Exposure .............................................................................................................. 81
    8.6.2. Adverse Events .................................................................................................................. 81
    8.6.3. Laboratory Evaluations ..................................................................................................... 82
    8.6.4. Bone Safety Evaluations .................................................................................................... 82
    8.6.5. Other Safety Evaluations .................................................................................................... 82
  8.7. Pharmacokinetic Analysis .......................................................................................................... 82
  8.8. Biomarker Analysis ...................................................................................................................... 83
  8.9. Patient Report Outcomes (PRO) ............................................................................................... 83
  8.10. Sample Size .............................................................................................................................. 83
  8.11. Data Monitoring Committee .................................................................................................. 83
  8.12. Analysis Schedule ..................................................................................................................... 84

9. RESPONSIBILITIES ....................................................................................................................... 85
  9.1. Investigator Responsibilities ..................................................................................................... 85
    9.1.1. Good Clinical Practice ....................................................................................................... 85
    9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) Review and Approval ................................................................................................................. 85
    9.1.3. Informed Consent ............................................................................................................... 85
    9.1.4. Confidentiality .................................................................................................................... 86
    9.1.5. Study Files and Retention of Records ............................................................................... 86
    9.1.6. Case Report Forms ............................................................................................................. 87
    9.1.7. Investigational Medicinal Product Accountability and Return ......................................... 88
    9.1.8. Inspections ......................................................................................................................... 88
    9.1.9. Protocol Compliance .......................................................................................................... 88
  9.2. Sponsor Responsibilities ............................................................................................................ 89
    9.2.1. Protocol Modifications ....................................................................................................... 89
    9.2.2. Study Report and Publications .......................................................................................... 89
  9.3. Joint Investigator/Sponsor Responsibilities ............................................................................... 89
    9.3.1. Payment Reporting .............................................................................................................. 89
    9.3.2. Access to Information for Monitoring ............................................................................... 90
    9.3.3. Access to Information for Auditing or Inspections .......................................................... 90
    9.3.4. Study Discontinuation ....................................................................................................... 90

10. REFERENCES ............................................................................................................................... 91

11. APPENDICES ............................................................................................................................. 92
LIST OF IN-TEXT TABLES

Table 1-1. GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following Single Doses of GS-9883 in Healthy Subjects (GS-9883 PK Analysis Set; Part A: Single Dosing) ..........21
Table 1-2. GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose Following Multiple-Dose Administration of GS-9883 (Analysis Set: GS-9883 PK Part B: Multiple-Dose) ...........................................................................................................22
Table 1-3. GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic Parameters Following Single-Dose Administration of GS-9883 in the Fasted and Fed States (GS-9883 PK Analysis Set) ....................................................................................................23
Table 1-4. Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values (GS-9883 PK Analysis Set) .........................................................24
Table 1-5. GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values .................................................................................................35
Table 5-1. Prior and Concomitant Medications .......................................................................................48

LIST OF IN-TEXT FIGURES

Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA (log_{10} copies/mL) (PP Analysis Set) .........................................................................................................................24
Figure 3-1. Study Schema .........................................................................................................................39
Figure 6-1. Virologic Rebound Schema .........................................................................................................66
PROTOCOL SYNOPSIS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

IND Number: 125589
EudraCT Number: 2015-004024-54
Clinical Trials.gov Identifier: NCT02607930

Study Centers Planned: Approximately 150 centers in North America, Europe and Latin America

Objectives: The primary objective of this study is:

- To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naïve-adult subjects as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 48

The secondary objectives of this study are:

- To evaluate the efficacy, safety, and tolerability of the two treatment groups through Weeks 48 and 96
- To evaluate the bone safety of the two treatment groups as determined by the percentage change from baseline in hip and spine bone mineral density (BMD) through Weeks 48 and 96

Study Design: Randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of GS-9883/F/TAF FDC versus ABC/DTG/3TC FDC in HIV-1 infected, antiretroviral treatment-naïve adult subjects. Subjects who provide written consent and meet all eligibility criteria will be randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1: FDC of GS-9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to food (n=300)

Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food (n=300)

Randomization will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL, > 100,000 to ≤ 400,000 copies/mL, or > 400,000 copies/mL) at screening, CD4+ cell count (< 50 cells/μL, 50 – 199 cells/μL, or ≥ 200 cells/μL) at screening, and region (US vs. Ex-US) at randomization.

Number of Subjects
Planned: Approximately 600 subjects in total. 300 subjects in each Treatment Group 1 and Treatment Group 2

Target Population: Antiretroviral treatment-naïve (except the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening), HLA-B*5701 negative, HIV-1 infected adults with plasma HIV-1 RNA levels ≥ 500 copies/mL and a screening genotype showing sensitivity to FTC, TFV, 3TC, and ABC.

Duration of Treatment: Subjects will be treated for at least 96 weeks. Subjects’ treatments will be unblinded after the last subject completes the Week 96 visit and Gilead completes the Week 96 analysis. Subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. At the Unblinding Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

Subjects who complete the study through the Unblinding Visit and do not continue on the open-label GS-9883/F/TAF FDC extension phase, will be required to return to the clinic 30 days after unblinding visit for a 30-Day Follow-Up Visit.
Diagnosis and Main Eligibility Criteria:  
Medically stable HIV-1 infected subjects who meet the following criteria:

- Plasma HIV-1 RNA levels \( \geq 500 \) copies/mL at screening
- Antiretroviral treatment naïve (\( \leq 10 \) days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for PrEP or PEP, up to one month prior to screening.
- Screening genotype report must show sensitivity to FTC, TFV, 3TC, and ABC
- Negative screening test for HLA-B*5701 allele
- Estimated GFR \( \geq 50 \) mL/min according to the Cockcroft-Gault formula for creatinine clearance
- No chronic Hepatitis B Virus (HBV) infection, as determined by either
  - Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit
  - Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit

Study Procedures/ Frequency:  
After screening procedures, eligible subjects will be randomized 1:1 to Treatment Group 1 or Treatment Group 2 and treated for 96 weeks. Following the Day 1 visit, subjects will be required to return for study visits at Weeks 4, 8, and 12, and then every 12 weeks from Week 12 through Week 96. After 96 weeks, subjects will continue to take their blinded study drugs and attend study visits every 12 weeks until treatment assignments have been unblinded.

For all eligible subjects, blood will be collected at Day 1, Weeks 4, 8, 12, and then every 12 weeks through the Unblinding Visit. Laboratory analyses (hematology, chemistry, and urinalysis), HIV-1 RNA, CD4+ cell count, and complete or symptom directed physical examinations will be performed at Screening, Day 1 and all subsequent visits. In addition, blood will be collected and stored for possible evaluation of markers of inflammation and immune activation, which may include but are not limited to: cystatin-C, IL-6, hs-CRP, d-dimer, sCD14, and sCD163. Platelet function evaluations may also be assessed, including but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand. Urine will be collected for evaluations of renal tubular function including urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2 microglobulin.
For all subjects on study drug, except subjects located in Germany, dual energy x-ray absorptiometry (DXA) scans will be performed prior to or within 24 hours of the Day 1 Visit, and then at Weeks 24, 48, 96, and at the Unblinding Visit or Early Study Drug Discontinuation Visit, if > 12 weeks since last scan. DXA scan results will be provided to study sites when available.

Adverse events and concomitant medications will be assessed at each visit.

### Test Product, Dose, and Mode of Administration:
FDC of GS-9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily without regard to food.

### Reference Therapy, Dose, and Mode of Administration:
FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily without regard to food.

### Criteria for Evaluation:

**Safety:** Adverse events, clinical laboratory tests and DXA

**Efficacy:**

- The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 48 as defined by the United States (US) Food and Drug Administration (FDA)-defined snapshot algorithm

The secondary efficacy endpoints include:

- The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 as defined by the US FDA-defined snapshot algorithm
- The proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 as defined by the US FDA-defined snapshot algorithm
- The change from baseline in $\log_{10}$ HIV-1 RNA and CD4+ cell count at Weeks 48 and 96

**Pharmacokinetics:** An intensive pharmacokinetic (PK) substudy will be performed at the Weeks 4 or 8 visits in a subset of subjects (target n=30) at study sites able to conduct this testing.

For all subjects on study drug a single anytime pre or post-dose PK blood sample will be collected at Weeks 8, 24 and 36.
For all subjects on study drug a trough PK blood sample will be obtained 20-28 hours following the last dose at Weeks 4 and 12. Following an observed dose, one post-dose PK blood sample will be collected between 1 and 4 hours post-dose.

For intensive PK substudy, the following PK parameters for GS-9883 may be explored as applicable:

\( C_{\text{max}}, T_{\text{max}}, T_{\text{last}}, C_{\text{min}}, T_{1/2}, AUC_{\text{min}}, AUC_{0-\text{last}}, Vz/F, CLss/F \).

The concentration of GS-9883 may be summarized using descriptive statistics. The pharmacokinetics of GS-9883 may be evaluated using population approaches. TAF and FTC concentrations may be analyzed and PK parameters may be summarized as applicable.

Optional Genomic Testing:

PPD

Optional Peripheral Blood Mononuclear Cell Substudy:

PPD

Patient Reported Outcome:

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) will be administered at Day 1, Weeks 4, 12, and 48.

Statistical Methods:

The primary analysis will consist of a non-inferiority test of GS-9883/F/TAF versus ABC/DTG/3TC, with respect to the proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm.
It will be concluded that GS-9883/F/TAF is non-inferior to ABC/DTG/3TC if the lower bound of the 2-sided 95% confidence interval (CI) of the difference (GS-9883/F/TAF – ABC/DTG/3TC) in the response rate (HIV-1 RNA < 50 copies/mL as defined by the US FDA-defined snapshot algorithm) is greater than -12%; ie, a margin of 12% is applied to non-inferiority assessment. The 95% CI will be constructed using a normal approximation method based on stratified Mantel-Haenszel proportions, where stratification factors include baseline HIV-1 RNA level (≤ 100,000 copies/mL vs. > 100,000 copies/mL) and region (US vs. Ex-US).

The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 and the proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 as defined by the US FDA-defined snapshot algorithm will also be summarized. The 95% CIs will be constructed in the same manner as described for the primary efficacy endpoint.

The change from baseline in log_{10} HIV-1 RNA and CD4+ cell count at Weeks 48 and 96 will be summarized by treatment using descriptive statistics. The differences and the associated 2-sided 95% CIs will be constructed using an Analysis of Variance (ANOVA) model, including treatment (GS-9883/F/TAF vs. ABC/DTG/3TC), baseline HIV-1 RNA level (≤ 100,000 copies/mL vs. > 100,000 copies/mL), and region (US vs. Ex-US) as fixed effects in the model.

The percentage change from baseline in hip and spine BMD at Weeks 48 and 96 will be summarized by treatment using descriptive statistics. The differences and the associated 2-sided 95% CIs will be conducted using an ANOVA model including treatment as a fixed effect in the model. Adverse events, clinical laboratory assessments, and pharmacokinetic parameters will be summarized using descriptive statistics.

A total of approximately 600 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment groups (300 subjects per treatment group), achieves at least 95% power to detect a non-inferiority margin of 12% in Week 48 response rate (HIV-1 RNA < 50 copies/mL as defined by the US FDA-defined snapshot algorithm) difference between the 2 treatment groups. For sample size and power computation, it is assumed that both treatment groups have a response rate of 91% (based on Gilead Studies GS-US-292-0104 and GS-US-292-0111), that a non-inferiority margin is 12%, and that the significance level of the test is at a one-sided 0.025 level.
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) including archiving of essential documents.
### GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>°C</td>
<td>degrees Celsius</td>
</tr>
<tr>
<td>°F</td>
<td>degrees Fahrenheit</td>
</tr>
<tr>
<td>ABC/3TC</td>
<td>abacavir/lamivudine, Epzicom® Kivexa®</td>
</tr>
<tr>
<td>ABC/DTG/3TC</td>
<td>abacavir/dolutegravir/lamivudine, Triumeq®</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil counts</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the plasma/serum/peripheral blood mononuclear cell concentration versus time curve</td>
</tr>
<tr>
<td>BID</td>
<td>twice a day</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CLcr</td>
<td>creatinine clearance</td>
</tr>
<tr>
<td>Cmax</td>
<td>the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) concentration of drug</td>
</tr>
<tr>
<td>CMH</td>
<td>Cochran-Mantel-Haenszel</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COBI, /co</td>
<td>cobicistat (GS-9350)</td>
</tr>
<tr>
<td>Ctau</td>
<td>the observed drug concentration at the end of the dosing interval</td>
</tr>
<tr>
<td>CPK</td>
<td>creatine phosphokinase</td>
</tr>
<tr>
<td>CRF</td>
<td>case report form(s)</td>
</tr>
<tr>
<td>CRO</td>
<td>contract (or clinical) research organization</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DHHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSPH</td>
<td>Drug Safety and Public Health</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir, Tivicay®</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form(s)</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EVG</td>
<td>elvitegravir</td>
</tr>
<tr>
<td>E/C/F/TAF</td>
<td>elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide</td>
</tr>
<tr>
<td>E/C/F/TDF</td>
<td>elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Stribild®</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FDA</td>
<td>(United States) Food and Drug Administration</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed dose combination</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>FTC/TAF</td>
<td>emtricitabine/tenofovir alafenamide</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>FTC, F</td>
<td>emtricitabine, Emtriva®</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice (Guidelines)</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma glutamyl transferase</td>
</tr>
<tr>
<td>GLSM</td>
<td>geometric least squares mean</td>
</tr>
<tr>
<td>GSI</td>
<td>Gilead Sciences, Inc.</td>
</tr>
<tr>
<td>GS-9883/F/TAF</td>
<td>GS-9883/emtricitabine/tenofovir alafenamide</td>
</tr>
<tr>
<td>HAART</td>
<td>highly active antiretroviral therapy</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HBcAb</td>
<td>hepatitis B core antibody</td>
</tr>
<tr>
<td>HBsAb</td>
<td>hepatitis B surface antibody</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HDPE</td>
<td>high-density polyethylene</td>
</tr>
<tr>
<td>hERG</td>
<td>human Ether-à-go-go-Related Gene</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HIV Sx</td>
<td>HIV Symptoms Distress Module</td>
</tr>
<tr>
<td>HLA</td>
<td>human leukocyte antigen</td>
</tr>
<tr>
<td>IB</td>
<td>investigator’s brochure</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent Data Monitoring Committee</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug (Application)</td>
</tr>
<tr>
<td>INSTI</td>
<td>integrase strand-transfer inhibitors</td>
</tr>
<tr>
<td>IRB</td>
<td>institutional review board</td>
</tr>
<tr>
<td>IWRS</td>
<td>interactive web response system</td>
</tr>
<tr>
<td>KS</td>
<td>Kaposi’s sarcoma</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LLN</td>
<td>lower limit of the normal range</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MH</td>
<td>Mantel-Haenszel</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters mercury</td>
</tr>
<tr>
<td>nM</td>
<td>nanoMolar</td>
</tr>
<tr>
<td>NNRTI</td>
<td>non-nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no observed adverse effect level</td>
</tr>
<tr>
<td>NRTI</td>
<td>nucleoside/nucleotide reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>PEP</td>
<td>post-exposure prophylaxis</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
</tbody>
</table>
PI | protease inhibitor
---|---
PK | pharmacokinetic
PSQI | Pittsburgh Sleep Quality Index
PrEP | pre-exposure prophylaxis
PTM | placebo-to-match
PT | preferred term
PT | prothrombin time
QD | once daily
RAL | raltegravir
RNA | ribonucleic acid
SA | single agent
SAE | serious adverse event
SF-36 | Short Form 36 Health Survey
SUSAR | Suspected Unexpected Serious Adverse Reaction
TAF | tenofovir alafenamide
TDF | tenofovir disoproxil fumarate, Viread®
TFV-DP | tenofovir diphosphate (TFVpp)
$t_{max}$ | the time (observed time point) of $C_{max}$
TSH | thyroid stimulating hormone
UGT1A1 | uridine 5’-diphospho-glucuronosyltransferase
UGT | uridine glucuronosyltransferase
ULN | upper limit of the normal range
US | United States
WPAI | Work Productivity and Activity Impairment Questionnaire
1. INTRODUCTION

1.1. Background

Human immunodeficiency virus-1 (HIV-1) infection is a life-threatening and serious disease that is of major public health interest around the world. There are approximately 2.4 million people in North America and Western and Central Europe living with HIV-1 and 36 million people worldwide {The Joint United Nations Programme 2014}. The infection, if left untreated or suboptimally treated, is characterized by deterioration in immune function, ultimately resulting in death. Therapeutic strategies for the treatment of HIV-1 disease have been significantly advanced by the availability of highly active antiretroviral therapy (HAART); the introduction of HAART was associated with a dramatic decrease in acquired immune deficiency syndrome (AIDS)-related morbidity and mortality {Palella et al 1998}, {Mocroft et al 1998}, {Sterne et al 2005}.

The success of potent and well-tolerated ART means that morbidity and mortality in the HIV-infected population is increasingly driven by non-AIDS–associated comorbidities. Clinical attention has become more focused on the optimization of tolerability, long-term safety, and adherence of potent ART regimens {Costagliola 2014}. In addition, there remains a significant medical need for new, effective therapies that take into consideration HIV genetic variability, the aging HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen simplification.

For ART-naive HIV-infected patients, current treatment guidelines suggest that initial therapy consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {Department for Health and Human Services (DHHS) 2015}. Virologically suppressed, HIV-infected patients may switch from their current regimen because of safety or tolerability concerns or for regimen simplification. All patient populations may benefit from once-daily fixed-dose combination (FDC) regimens as these have been shown to provide increased adherence and improved clinical and virologic outcomes {Sterrantino et al 2012}, {Aldir et al 2013}.

Tenofovir (TFV) is a nucleotide analog that inhibits HIV-1 reverse transcription. While tenofovir disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy, nephrotoxicity is an identified risk, and reductions in bone mineral density (BMD) have been shown that are larger than those seen with other NRTIs. Tenofovir alafenamide (TAF) is also an oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP), and approximately 90% lower circulating levels of TFV relative to TDF at the clinical doses. The distinct metabolism of TAF offers the potential for an improved clinical profile compared with TDF.

GS-9883 is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Antiviral testing has shown that GS-9883 is active against a broad panel of HIV-1 viral lab strains and clinical isolates. GS-9883 is fully active against a panel of mutant
viruses with resistance to NRTI’s, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Integrase mutant viruses that are resistant to the INSTIs raltegravir (RAL) and elvitegravir (EVG) remain largely sensitive to GS-9883.

Gilead Sciences (Gilead) has coformulated GS-9883 with the NRTI emtricitabine (FTC; F) and the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use. This GS-9883/F/TAF FDC may provide a potent, convenient, tolerable, and practical regimen for the long-term treatment of patients with HIV infection.

1.2. GS-9883

1.2.1. General Information

GS-9883, a potent inhibitor of HIV-1 integrase is being evaluated for the treatment of HIV infection. Antiviral testing has shown that GS-9883 is active against a broad panel of HIV-1 viral lab strains and clinical isolates. GS-9883 is fully active against a panel of mutant viruses with resistance to NRTIs, NNRTIs, and PIs. Integrase mutant viruses that are resistant to the INSTIs RAL and EVG remain largely sensitive to GS-9883.

1.2.2. Preclinical Pharmacology and Toxicology

A core battery of safety pharmacology studies have been conducted with GS-9883. These include assessments of cytotoxicity, off-target receptor and ion-channel binding, effects on human Ether-à-go-go-Related Gene (hERG) potassium current and papillary muscle action potential, and in vivo studies in rats and dogs that evaluated effects of GS-9883 on all major organ systems. The volume of distribution of GS-9883 ranged between 0.09 and 0.22 L/kg in the preclinical species, which indicates that the distribution of GS-9883 is limited to the extracellular compartment due to its high binding to plasma proteins. The projected half-life of GS-9883 in humans is approximately 20 hours based upon the estimates of clearance and volume of distribution.

1.2.2.1. Pharmacology

GS-9883 has IC$_{50}$ values ranging from 1.5 to 2.4 nM, similar to the inhibitory effect of DTG and EVG. GS-9883 is highly potent against HIV replication in MT4 cells with an EC$_{50}$ (50% effective inhibitory concentration) value of 1.9 nM and a protein adjusted EC$_{95}$ value of 361 nM. GS-9883 does not show significant cytotoxicity against dividing and non-dividing human PBMCs, primary human hepatocytes and various non-target human cell lines.

GS-9883 is mainly metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT1A1) and CYP3A. GS-9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up to 25 μM. Consequently, GS-9883 is unlikely to be a clinically relevant inhibitor of these enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by these enzymes. GS-9883 only modestly inhibits renal transporter OCT2 (IC$_{50}$ = 0.42 μM). As a result, GS-9883 is not expected to significantly interfere with the key transporter responsible for creatinine tubular elimination at the clinically projected C$_{max}$. Additionally, the risk that GS-9883 will affect the OCT2-mediated excretion of co-administered drugs is considered to be low.
GS-9883 does not activate AhR and only weakly activates PXR at concentrations up to 50 μM (less than 5% and 40% of activation, respectively, compared to positive control compound). Therefore, GS-9883 is not expected to act as an inducer through PXR- or AhR-mediated pathways at the doses and exposure levels projected in clinical use.

1.2.2.2. Toxicology

Single oral doses of GS-9883 up to 1000 mg/kg were well-tolerated in rats (AD-141-2286). The increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg (AUC₀₋₂₄ 2205 μg·h/mL and 1931 μg·h/mL, respectively). In monkeys, single oral doses of GS-9883 up to 1000 mg/kg were well-tolerated (AD-141-2284). The increase in exposure was limited (< 2-fold) between 300 to 1000 mg/kg (AUC₀₋₂₄ 803 μg·h/mL and 1078 μg·h/mL, respectively).

In 2-week (TX-141-2029) and 26-week (TX-141-2031) oral toxicity studies in rats at doses up to 300 mg/kg/day, GS-9883 was well-tolerated with no GS-9883-related effects on clinical observations, body weight, food consumption, ophthalmic examinations, and anatomic pathology. The high dose of 300 mg/kg/day was considered the maximum feasible dose based upon saturation of absorption. The no observed effect level (NOEL) in the 26-week study was considered to be the high dose of 300 mg/kg/day. At the NOEL, GS-9883 exposures in the rat were considered to be approximately 12-/31-fold higher (males/females) than the projected steady state human exposure of GS-9883 following administration of GS-9883/F/TAF (50/200/25 mg) QD under fed conditions.

In a 39-week study in monkeys (TX-141-2032), following administration of 1000 mg/kg/day (high dose) of GS-9883 for 39 weeks, pathology data indicated minimal to marked bile duct hyperplasia and minimal or moderate hepatocyte hypertrophy in both sexes, and minimal regenerative hyperplasia and minimal or slight neutrophil infiltrate in males. The macroscopic finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with moderate hepatocyte hypertrophy and marked bile duct hyperplasia. After a 4-week recovery period, GS-9883-related microscopic liver findings included marked bile duct hyperplasia, slight hepatocyte hypertrophy, minimal regenerative hyperplasia, and slight lymphocyte infiltrate in one male and slight bile duct hyperplasia in one female administered 1000 mg/kg/day, while the other two animals in the high dose group had no hepatobiliary findings. Minimally to mildly increased ALT activities (≤ 3.5-fold versus baseline values), likely associated with liver findings, exhibited reversibility. There were no other adverse findings in the study, including clinical observations, or effects on body weight, body weight change, food consumption, ECGs, hematology, coagulation, clinical chemistry, urinalysis, and ophthalmoscopy.

No GS-9883-related effects were observed in the mid-dose group (200 mg/kg/day) which was considered the no-observed-effect-level (NOEL). The estimated margin of exposure at the NOEL was approximately 5.1-fold based on expected human exposure with the once daily dosing of the GS-9883/F/TAF (50/200/25 mg) tablet.
A standard battery of in vitro and in vivo studies was performed to assess the genotoxic potential of GS-9883. There was no evidence of mutagenic or clastogenic activity in an in vitro bacterial reverse mutation assay (Study TX-141-2026), a chromosomal aberration assay in human lymphocytes (Study TX-141-2027), or in a rat micronucleus test (Study TX-141-2029).

1.2.3. Clinical Trials of GS-9883

Clinical trials entailing the use of GS-9883 include:

- GS-US-141-1218, a Phase 1 double blind, randomized, placebo-controlled, first-in-human, single- and multiple-ascending dose study evaluating the safety, tolerability, and PK of oral GS-9883 in healthy subjects and a randomized, open-label, 2-cohort, 3-period, crossover, PK study evaluating the drug interaction potential between F/TAF FDC tablet and GS-9883 in healthy subjects (completed)

- GS-US-141-1219, a Phase 1b randomized, double-blinded, sequential cohort placebo-controlled study of the safety, PK, and antiviral activity of GS-9883 in HIV-1 infected subjects (5 mg, 25 mg, 50 mg, 100 mg) (completed)

- GS-US-141-1233, a Phase 1, Open-label, Two-Cohort, Multiple-Period, Fixed-Sequence, Crossover Study to Evaluate 1) the Relative Bioavailability of Two GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg) Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet Administered Simultaneously and 2) the Effect of Food on the Pharmacokinetics of GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg) Fixed-Dose Combination Tablets (in life portion completed)

- GS-US-141-1479, a Phase 1, open-label, parallel-group, adaptive single-dose study to evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)

- GS-US-141-1480, a Phase 1 partially-blinded, randomized, placebo- and positive-controlled study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy subjects (completed)

- GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and excretion of GS-9883 in healthy subjects (completed)

- GS-US-141-1485, a Phase 1 adaptive study to evaluate transporter, CYP-mediated and UGT1A1 drug-drug interactions between GS-9883 and probe drugs (completed)

- GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo-Controlled Phase 1 Study Evaluating the Effect of GS-9883 on Renal Function as Assessed by Markers of Glomerular Filtration Rate (in life portion completed)
• GS-US-311-1790, a Phase 1 Randomized, Open Label, Drug Interaction Study Evaluating the Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (completed)

• GS-US-380-1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug-Drug Interaction Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate (GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) Tablets (completed)

• GS-US-141-1475, a Phase 2 Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (ongoing).

Please refer to the GS-9883/F/TAF Investigators’ Brochure for further information about these studies.

1.2.3.1. Phase 1 Safety and Pharmacokinetics

Study GS-US-141-1218 was a four part, first-in-human study. Parts A and B were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies of GS-9883 in healthy male and female subjects. Part C was an open label, fixed sequence food effect study evaluating the effect of food on the PK of GS-9883. Part D was a randomized, open-label, 2-cohort, 3-period, crossover PK study evaluating the drug interaction potential between FTC/TAF FDC tablet and GS-9883 in healthy subjects.

There was no difference in the overall incidence or type of AEs when GS-9883 was administered in the fasted and fed states. There was no difference in the overall incidence of AEs when GS-9883 or FTC/TAF was each administered alone or in combination.

No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any cohort.

Changes in serum creatinine were observed in this study, presumably via inhibition of the renal transporter OCT2. In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 0.05 mg/dL for the 5 mg cohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), conducted in the fed state (regular meal), subjects received 100 mg GS-9883 monotherapy for 7 days and 100 mg GS-9883 with FTC/TAF for 7 days, the mean serum creatinine change at Day 7 was 0.14 mg/dL following GS-9883 and 0.17 mg/dL following GS-9883 + FTC/TAF. All changes returned to baseline after discontinuation of GS-9883.

The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. Grade 3 laboratory abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood. All of these subjects were female, none of the labs were considered by the Investigator to be clinically significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory abnormalities were observed.
Based on results in study GS-US-141-1218, pharmacokinetic profile of GS-9883 was characterized by rapid absorption with time to peak plasma concentrations (median T$_{\text{max}}$ of cohorts) ranging between 1 and 4 hours following administration under fasted conditions. GS-9883 exposures were appropriately dose proportional following single dose 25-100 mg dose administration, with decreasing dose proportional at higher doses. The half-life of GS-9883 was approximately 18 hours, with no changes observed across studied dose range as evidenced by parallel terminal phase slopes. A high-fat meal increased AUC$_{\text{inf}}$ and C$_{\text{max}}$ (geometric mean, 84% and 101%, respectively) following 100 mg single dose administration. Steady state was achieved after 4-6 days of once daily dosing of GS-9883 with average accumulation ratios for AUC$_{24\text{hr}}$ of 1.6.

### Table 1-1. GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following Single Doses of GS-9883 in Healthy Subjects (GS-9883 PK Analysis Set; Part A: Single Dosing)

<table>
<thead>
<tr>
<th>GS-9883 PK Parameter</th>
<th>5 mg (N=6)</th>
<th>25 mg (N=6)</th>
<th>50 mg (N=6)</th>
<th>100 mg (N=6)</th>
<th>300 mg (N=6)</th>
<th>600 mg (N=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C$_{\text{max}}$ (ng/mL)</td>
<td>691.2 (22.1)</td>
<td>1618.3 (26.7)</td>
<td>3965.0 (40.1)</td>
<td>6998.3 (36.1)</td>
<td>14605.0 (27.1)</td>
<td>20050.0 (7.5)</td>
</tr>
<tr>
<td>T$_{\text{max}}$ (hr)</td>
<td>1.25 (1.00-1.50)</td>
<td>2.00 (1.00-3.00)</td>
<td>3.00 (1.50-4.00)</td>
<td>2.25 (1.50-3.00)</td>
<td>3.50 (2.00-6.00)</td>
<td>3.5 (2.00-4.00)</td>
</tr>
<tr>
<td>AUC$_{\text{inf}}$ (ng.hr/mL)</td>
<td>13059.7 (25.1)</td>
<td>35718.2 (21.3)</td>
<td>78399.5 (29.7)</td>
<td>163028.2 (24.3)</td>
<td>355917.3 (32.9)</td>
<td>454446.8 (19.9)</td>
</tr>
<tr>
<td>T1/2 (hr)</td>
<td>18.51 (16.81-19.99)</td>
<td>18.08 (16.63-19.64)</td>
<td>16.72 (15.77-17.11)</td>
<td>18.90 (17.96-20.05)</td>
<td>18.14 (17.86-20.53)</td>
<td>17.89 (16.38-19.52)</td>
</tr>
</tbody>
</table>

T1/2 and Tmax: Median (Q1, Q3)

Table 1-2 presents GS-9883 plasma PK parameters following administration of GS-9883 (5, 25, 50, 100, and 300 mg) once daily for 7 days. Following administration of either GS-9883 (5, 25, 50, 100, or 300 mg) once daily for 7 days, the PK absorption profile observed on Days 1 and 7 was similar to that observed in Part A (SAD). The median T$_{\text{max}}$ values ranged from 1.5 to 2.5 hours on Day 1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing GS-9883 AUC and C$_{\text{max}}$ on Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels of GS-9883 were achieved between Study Days 4 to 6 of dosing and maintained through Day 14. Accumulation is approximately 1.6-fold, which is consistent with the observed half-life of the GS-9883 (approximately 18 hours).
Table 1-2. GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose Following Multiple-Dose Administration of GS-9883 (Analysis Set: GS-9883 PK Part B: Multiple-Dose)

<table>
<thead>
<tr>
<th>GS-9883 PK Parameter Mean (%CV)*</th>
<th>Multiple-Dose GS-9883</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 mg (N = 6)</td>
</tr>
<tr>
<td></td>
<td>25 mg (N = 6)</td>
</tr>
<tr>
<td></td>
<td>50 mg (N = 6)</td>
</tr>
<tr>
<td></td>
<td>100 mg (N = 6)</td>
</tr>
<tr>
<td></td>
<td>300 mg (N = 6)</td>
</tr>
<tr>
<td><strong>Day 1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>AUC&lt;sub&gt;0-24&lt;/sub&gt; (hr*ng/mL)</strong></td>
<td>9033.6 (8.2)</td>
</tr>
<tr>
<td></td>
<td>27,775.1 (28.3)</td>
</tr>
<tr>
<td></td>
<td>58,371.4 (18.9)</td>
</tr>
<tr>
<td></td>
<td>79,773.8 (18.9)</td>
</tr>
<tr>
<td></td>
<td>180,714.3 (17.6)</td>
</tr>
<tr>
<td><strong>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</strong></td>
<td>709.7 (9.5)</td>
</tr>
<tr>
<td></td>
<td>2220.0 (35.6)</td>
</tr>
<tr>
<td></td>
<td>4648.3 (18.7)</td>
</tr>
<tr>
<td></td>
<td>6248.3 (26.8)</td>
</tr>
<tr>
<td></td>
<td>13,716.7 (19.1)</td>
</tr>
<tr>
<td><strong>T&lt;sub&gt;max&lt;/sub&gt; (hr)</strong></td>
<td>1.50 (1.50, 1.50)</td>
</tr>
<tr>
<td></td>
<td>1.75 (1.00, 3.00)</td>
</tr>
<tr>
<td></td>
<td>1.50 (1.00, 2.00)</td>
</tr>
<tr>
<td></td>
<td>2.50 (2.00, 3.00)</td>
</tr>
<tr>
<td></td>
<td>2.50 (2.00, 4.00)</td>
</tr>
<tr>
<td><strong>Day 7</strong></td>
<td></td>
</tr>
<tr>
<td><strong>AUC&lt;sub&gt;tau&lt;/sub&gt; (hr*ng/mL)</strong></td>
<td>14,392.0 (16.7)</td>
</tr>
<tr>
<td></td>
<td>50,008.2 (26.6)</td>
</tr>
<tr>
<td></td>
<td>89,710.1 (22.7)</td>
</tr>
<tr>
<td></td>
<td>126,785.8 (23.7)</td>
</tr>
<tr>
<td></td>
<td>277,200.2 (16.7)</td>
</tr>
<tr>
<td><strong>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</strong></td>
<td>982.5 (7.9)</td>
</tr>
<tr>
<td></td>
<td>3455.0 (24.1)</td>
</tr>
<tr>
<td></td>
<td>6538.3 (17.6)</td>
</tr>
<tr>
<td></td>
<td>9396.7 (20.8)</td>
</tr>
<tr>
<td></td>
<td>19,900.0 (21.2)</td>
</tr>
<tr>
<td><strong>C&lt;sub&gt;tau&lt;/sub&gt; (ng/mL)</strong></td>
<td>400.83 (26.9)</td>
</tr>
<tr>
<td></td>
<td>1322.00 (27.8)</td>
</tr>
<tr>
<td></td>
<td>2241.67 (28.2)</td>
</tr>
<tr>
<td></td>
<td>3145.00 (26.1)</td>
</tr>
<tr>
<td></td>
<td>6758.33 (21.6)</td>
</tr>
<tr>
<td><strong>T&lt;sub&gt;max&lt;/sub&gt; (hr)</strong></td>
<td>1.50 (1.00, 2.00)</td>
</tr>
<tr>
<td></td>
<td>3.00 (2.00, 3.00)</td>
</tr>
<tr>
<td></td>
<td>1.75 (1.50, 2.00)</td>
</tr>
<tr>
<td></td>
<td>1.75 (1.50, 3.00)</td>
</tr>
<tr>
<td></td>
<td>4.00 (2.00, 4.00)</td>
</tr>
<tr>
<td><strong>Accumulation Ratio of AUC (%)</strong></td>
<td>160.5 (19.0)</td>
</tr>
<tr>
<td></td>
<td>182.2 (17.1)</td>
</tr>
<tr>
<td></td>
<td>154.0 (15.9)</td>
</tr>
<tr>
<td></td>
<td>158.5 (12.1)</td>
</tr>
<tr>
<td></td>
<td>157.5 (22.6)</td>
</tr>
</tbody>
</table>

* Data are presented as mean (%CV), except for T<sub>max</sub> and t<sub>1/2</sub>, which are presented as median (Q1, Q3)

Table 1-3 presents the geometric least squares mean (GLSM) ratios and associated 90% CIs for the test (fed) versus reference (fasted) treatments for the primary plasma PK parameters of GS-9883. Administration of a single dose of GS-9883 100 mg with food (high-calorie/high-fat breakfast) increased the GLSM values of C<sub>max</sub> and AUC<sub>inf</sub> 101% (90% CI of GLSM ratio 165.93% to 242.74%) and 84% (90% CI of GLSM ratio 152.05% to 222.59%), respectively. There were no apparent changes in clearance and T<sub>1/2</sub> following administration with food, indicating that food enhanced the bioavailability of GS-9883 by improving its solubility and/or absorption.
Table 1-3. GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic Parameters Following Single-Dose Administration of GS-9883 in the Fasted and Fed States (GS-9883 PK Analysis Set)

<table>
<thead>
<tr>
<th>GS-9883 PK Parameter</th>
<th>Mean (%CV)</th>
<th>Test GS-9883 100 mg Fed (n=8)</th>
<th>Reference GS-9883 100 mg Fasted (n=8)</th>
<th>% GLSM Ratio (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_{inf} (hr*ng/mL)</td>
<td>214,146.3 (15.9)</td>
<td>117,777.1 (23.3)</td>
<td>183.97 (152.05, 222.59)</td>
<td></td>
</tr>
<tr>
<td>AUC_{last} (hr*ng/mL)</td>
<td>209,259.9 (15.1)</td>
<td>115,681.7 (24.0)</td>
<td>183.58 (151.91, 221.86)</td>
<td></td>
</tr>
<tr>
<td>C_{max} (ng/mL)</td>
<td>11,268.8 (15.1)</td>
<td>5885.0 (34.9)</td>
<td>200.69 (165.93, 242.74)</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; GLSM = geometric least squares mean

1.2.3.2. Phase 1 b Proof of Concept

The first HIV-1 positive human subjects were dosed in the fasted state with 10 days of GS-9883 in study (GS-US-141-1219). Four cohorts of 5 subjects each were randomized 4:1 to receive GS-9883 or placebo to match at doses of 5 mg, 25 mg, 50 mg, and 100 mg once daily for 10 days.

GS-9883 was generally well tolerated at the doses evaluated. A total of 9 of 20 subjects had an AE in this study. The most frequently reported AEs across all subjects were diarrhea (2 subjects), and headache (3 subjects). No other AE was reported in more than 1 subject. There was no increase in the incidence of AEs with increasing doses of GS-9883.

The majority of AEs were considered by the investigator to be not related to study drug. A total of 2 subjects experienced mild diarrhea that was considered related to study drug (1 in the 5 mg cohort, 1 in the 100 mg cohort).

No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to discontinuation of study drug were reported in any cohort.

The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. No Grade 3 treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL (100 mg). These changes in serum creatinine appeared to be transient and returned close to baseline values on discontinuation of study drug. One Grade 4 new onset laboratory abnormality was seen in 1 subject who received 5 mg GS-9883. This was a Grade 4 CPK seen on Day 17, 7 days following his last dose of study medication. The subject was asymptomatic. The Investigator felt that this was unrelated to study medication and was due to resumption of crystal methamphetamine use by the subject. An adverse event of elevated CK was reported unrelated to study medication.

Based on PK information collected in study GS-US-141-1219, which was in line with PK observed in study GS-US-141-1218, the median IQ for each dose were calculated and are presented in the Table 1-4 below.
Table 1-4. Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values (GS-9883 PK Analysis Set)

<table>
<thead>
<tr>
<th>GS-9883 dose</th>
<th>N</th>
<th>Median (range) C_{1au,ss} (ng/mL)</th>
<th>Median (range) palIQ95a</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>4</td>
<td>206.5 (146.0 to 342.0)</td>
<td>1.3 (0.9 to 2.1)</td>
</tr>
<tr>
<td>25 mg</td>
<td>4</td>
<td>797.5 (714.0 to 1900.0)</td>
<td>4.9 (4.4 to 11.7)</td>
</tr>
<tr>
<td>50 mg</td>
<td>4</td>
<td>2170.0 (852.0 to 3020.0)</td>
<td>13.4 (5.3 to 18.6)</td>
</tr>
<tr>
<td>100 mg</td>
<td>4</td>
<td>4190.0 (3730.0 to 5970.0)</td>
<td>25.9 (23.0 to 36.9)</td>
</tr>
</tbody>
</table>

a. The protein adjusted IQ95 (palIQ95) value is estimated based on steady-state C_{1au} values and the in vitro palC95 value for wild-type HIV-1 (162 ng/ml).

The mean and 95% CIs of change from baseline in HIV-1 RNA (log10 copies/mL) are presented in Figure 1-1.

Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA (log_{10} copies/mL) (PP Analysis Set)

NOTE: Baseline value was the last available value collected prior to the time of the first dose of study drug.
Mean viral load change on Day 11 was $-2.08 \log_{10}$ in the 25 mg cohort, $-2.06 \log_{10}$ in the 50 mg cohort, and $-2.43 \log_{10}$ in the 100 mg cohort. Time weighted average change from baseline at Day 11 (DAVG11) was $-0.92 \log_{10}$ in the 5 mg cohort, $-1.33 \log_{10}$ in the 25 mg cohort, $-1.37 \log_{10}$ in the 50 mg cohort and $-1.61 \log_{10}$ in the 100 mg cohort. Viral suppression (HIV-1 RNA < 50 copies/mL) was ever achieved by the end of the study (Day 17) by 1 subject (25.0%) in the GS-9883 50 mg group and 2 subjects (50%) in the GS-9883 100 mg group.

1.2.3.3. Summary of Phase 2 Study (GS-US-141-1475)

Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind, multicenter, active-controlled study to assess the safety and efficacy of a regimen containing GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV-infected, ART-naive adult subjects.

Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, stratified by HIV-1 RNA level ($\leq 100,000$ copies/mL, $> 100,000$ copies/mL to $\leq 400,000$ copies/mL, or $> 400,000$ copies/mL) at screening:

- Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo-to-match DTG 50 mg once daily
- Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo-to-match GS-9883 75 mg once daily

Week 24 interim data are summarized below.

**Subject Disposition and Baseline Characteristics**

A total of 98 subjects were randomized and treated in the study: 65 subjects in the GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group. At the time of the Week 24 data analysis, 2 subjects (2.0%) had prematurely discontinued from the study, 1 in each treatment group; both subjects were lost to follow-up.

Demographic and baseline characteristics were similar between the 2 treatment groups.

Key baseline disease characteristics (ie, viral load, CD4 cell count, and eGFR$_{CG}$) were similar between the 2 treatment groups.

Median (first quartile [Q1], third quartile [Q3]) baseline HIV-1 RNA was 4.45 (3.96, 4.79) log$_{10}$ copies/mL, with 82.7% of subjects having $\leq 100,000$ copies/mL at baseline; 5 subjects had $> 400,000$ copies/mL at baseline; 4 of these subjects were randomized to GS-9883+F/TAF and 1 subject was randomized to DTG+F/TAF.

Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/µL, with 41.8% of subjects having $\geq 500$ cells/µL at baseline. Median (Q1, Q3) baseline eGFR$_{CG}$ was 125.3 (105.7, 147.0) mL/min.
**Efficacy Results**

Virologic success at Weeks 12 and 24 was assessed using the US FDA-defined snapshot algorithm, defined as plasma HIV-1 RNA < 50 copies/mL. At Weeks 12 and 24, virologic success was high and similar between the 2 treatment groups as follows: Week 12 GS-9883+F/TAF 93.8%, DTG+F/TAF 93.9% (stratum-adjusted difference in percentages: −1.3%; 95% CI: −12.9% to 10.2%; p = 0.79); Week 24 GS-9883+F/TAF 95.4%, DTG+F/TAF 93.9% (1.0%; 95% CI: −10.7% to 12.7%; p = 0.84).

Of the 5 subjects with baseline viral load > 400,000 copies/mL, 4 had HIV-1 RNA < 50 copies/mL at Week 24, and 1 had HIV-1 RNA of 60 copies/mL.

Following initiation of study drug, the increases from baseline in CD4 cell count were similar between treatment groups. Mean (SD) baseline CD4 cell counts were as follows: GS-9883+F/TAF 471 (190.9) cells/μL; DTG+F/TAF 507 (271.0) cells/μL; p = 0.35. The mean (SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment groups as follows: GS-9883+F/TAF, +170 (150.0) cells/μL; DTG+F/TAF, +173 (220.5) cells/μL (difference in least squares mean [LSM]: 0; 95% CI: −76 to 76; p = 1.00). There were similar increases in the mean (SD) CD4 cell count in both treatment groups Week 24: GS-9883+F/TAF, +189 (177.8) cells/μL; DTG+F/TAF, +157 (163.2) cells/μL (difference in LSM: 39; 95% CI: −35 to 113; p = 0.30).

**Interim Virology Resistance Data**

Through Week 24, no emergent drug resistance was detected.

**Safety Results**

**Adverse Events**

The overall incidence of treatment-emergent AEs was balanced between treatment groups as follows: GS-9883+F/TAF 66.2%, 43 subjects; DTG+F/TAF 57.6%, 19 subjects. The most common treatment-emergent AEs (occurring in > 2 subjects) by treatment group were as follows:

- **GS-9883+F/TAF:** diarrhea and headache (7.7%, 5 subjects each); and nausea, decreased appetite, arthralgia, and cough (4.6%, 3 subjects each)

- **DTG+F/TAF:** nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects)

Most treatment-emergent AEs were Grade 1 in severity. Grade 3 or 4 AEs were reported in only 1 subject (Grade 3 diabetic ketoacidosis), in the GS-9883+F/TAF group; this event was also reported as an SAE. One other SAE (appendicitis), also in the GS-9883+F/TAF group, was reported. Neither SAE was considered related to study drug by the investigator or resulted in study drug discontinuation or interruption, and both SAEs resolved.
The overall incidence of study drug-related treatment-emergent AEs was balanced between treatment groups as follows: GS-9883+F/TAF 15.4%, 10 subjects; DTG+F/TAF 18.2%, 6 subjects. Most study drug-related treatment-emergent AEs were Grade 1 in severity. Grade 2 study drug-related treatment-emergent AEs were reported in 1 subject in the GS-9883+F/TAF group (somnolence and headache) and 1 subject in the DTG+F/TAF group (vomiting). There were no Grade 3 or 4 treatment-emergent AEs or SAEs reported that were considered related to study drug.

No Grade 4 AEs, deaths, pregnancies, or AEs leading to premature study drug discontinuation were reported in either treatment group.

Clinical Laboratory Evaluations

The percentage of subjects with at least 1 treatment-emergent laboratory abnormality (ie, at least 1 grade level increase from baseline in graded abnormality) was similar between treatment groups as follows: GS-9883+F/TAF 76.6%, 49 subjects; DTG+F/TAF 78.1%, 25 subjects. The majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. The percentage of subjects with at least 1 Grade 3 or 4 treatment-emergent laboratory abnormality was similar between treatment groups as follows: GS-9883+F/TAF 17.2%, 11 subjects; DTG+F/TAF 12.5%, 4 subjects. Grade 3 or 4 laboratory abnormalities occurring in at least 2 subjects in either treatment group were as follows: creatine kinase (GS-9883+F/TAF, 7.8% [5 subjects]), fasting serum glucose (DTG+F/TAF, 6.3% [2 subjects]), aspartate aminotransferase (AST) (GS-9883+F/TAF, 3.1% [2 subjects]), and fasting low-density lipoprotein (LDL) (GS-9883+F/TAF, 3.1% [2 subjects]). The only Grade 4 laboratory abnormalities were for creatine kinase, reported in 2 subjects (3.1%) in the GS-9883+F/TAF group. All increased creatine kinase values appeared to be transient, and none were associated with AEs. Of the 2 subjects with increased AST, 1 subject had Grade 3 AST and Grade 3 ALT at Week 24 in the setting of alcohol abuse; the other subject had Grade 3 AST at Week 8 that returned to normal by Week 24.

There were no clinically significant changes from baseline or differences between treatment groups in the median values for hematology, chemistry, or metabolic parameters. There were similar increases from baseline in median (Q1, Q3) serum creatinine in both treatment groups at Week 24: GS-9883+F/TAF 0.12 (0.06, 0.18) mg/dL; DTG+F/TAF 0.13 (0.05, 0.21) mg/dL. There were decreases in median (Q1, Q3) eGFR\textsubscript{CG} at Week 24, which were smaller in the GS-9883+F/TAF compared with the DTG+F/TAF group: GS-9883+F/TAF $-13.3$ ($-19.9$, $-4.0$) mL/min; DTG+F/TAF $-17.2$ ($-25.7$, $-6.9$) mL/min.

Conclusions

Key Week 24 conclusions from Study GS-US-141-1475 include the following:

- Virologic success at Week 24 when assessed using the US FDA-defined snapshot algorithm, defined as plasma HIV-1 RNA $< 50$ copies/mL, was similar between the 2 treatment groups as follows: GS-9883+F/TAF 95.4%; DTG+F/TAF 93.9%; stratum-adjusted difference in percentages: 1.0%; 95% CI: $-10.7$ to 12.7%; $p = 0.84$. There was a similar increase in the mean (SD) CD4 cell count between the 2 treatment groups, GS-9883+F/TAF, $+189$ (177.8) cells/μL; DTG+F/TAF, $+157$ (163.2) cells/μL (difference in LSM: 39; 95% CI: $-35$ to 113; $p = 0.30$).
• No resistance to any INSTIs, NRTIs, NNRTIs, or PIs was detected through Week 24.

• No AEs led to study drug discontinuation in either treatment group.

• Both GS-9883+F/TAF and DTG+F/TAF were generally well tolerated through 24 weeks of treatment. The most commonly reported treatment-emergent AEs were diarrhea and headache (7.7% each) in the GS-9883+F/TAF group and nausea (12.1%) and diarrhea (9.1%) in the DTG+F/TAF group. There were 2 SAEs, 1 of which was also a Grade 3 AE; neither of these events was considered related to study drug by the investigator, or led to study drug discontinuation. There were no other Grade 3 or 4 AEs, and no deaths, pregnancies, or AEs leading to premature study drug discontinuation reported. The percentage of subjects with at least 1 treatment-emergent laboratory abnormality was similar between treatment groups. The majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. There were similar increases from baseline in serum creatinine in both treatment groups at Week 24.

1.3. Information about Emtricitabine (Emtriva®, FTC)

Emtricitabine (5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan-5-yl] cytosine, FTC) is a NRTI that has demonstrated potent and selective inhibition of the HIV. In HIV-infected adults, FTC is administered as a 200 mg QD dose concurrently with other ARV drugs. The 200 mg FTC capsule formulation was approved by the US FDA for marketing on 2 July 2003 and is available under the name Emtriva®. In the European Union (EU), marketing authorization was granted for both the 200 mg Emtriva® capsule formulation and a 10 mg/mL Emtriva® oral Solution formulation on 24 October 2003, with indications for the treatment of HIV infection concurrently with other antiretroviral drugs in both adult and pediatric patients.

Further information is available in the current Prescribing Information for Emtriva®.

1.4. Information about Tenofovir alafenamide (TAF, GS-7340)

Tenofovir alafenamide (GS-7340, TAF) is a second generation oral prodrug of tenofovir (TFV), a nucleotide analog that inhibits HIV-1 reverse transcription. Tenofovir is metabolized intracellularly to the active metabolite, tenofovir diphosphate (TFV-DP), a competitive inhibitor of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. The intracellular metabolism of TAF and TFV are consistent with the 600-fold enhancement in anti-HIV activity in cell culture of TAF over TFV.

Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.4.1. **Clinical Trials of Single Agent Tenofovir alafenamide (TAF, GS-7340) or Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)**

Clinical trials entailing the use of tenofovir alafenamide include:

- GS-US-120-1101, a Phase 1/2 study of the pharmacokinetics and antiviral activity of GS-7340 (50 mg and 150 mg) in HIV-infected subjects (completed)

- GS-US-120-0104, a Phase 1b study of the pharmacokinetics and antiviral activity of GS-7340 (8 mg, 25 mg, 40 mg) in HIV-infected subjects (completed)

- GS-US-120-0107, a Phase 1, partially-blinded, randomized, placebo- and positive controlled study to evaluate the effect of GS-7340 on the QT/QTc interval in healthy subjects (completed)

- GS-US-120-0108, a Phase 1, open-label, parallel-design study to evaluate the pharmacokinetics of GS-7340 in subjects with severe renal impairment (completed)

- GS-US-120-0109, a Phase 1 study to evaluate the pharmacokinetics, metabolism and excretion of GS-7340 (completed)

- GS-US-120-0114, a Phase 1, open-label, parallel-group, single dose study to evaluate the pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic function (completed)

- GS-US-120-0117, a Phase 1 single-dose study evaluating the pharmacokinetic drug interaction potential between rilpivirine and tenofovir alafenamide (completed)

- GS-US-120-0118, a Pharmacokinetic study evaluating the drug interaction potential of tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in healthy subjects (completed)

- GS-US-311-1386, a Phase 1 study to determine the effect of food on the pharmacokinetics of tenofovir alafenamide when administered as F/TAF FDC in healthy volunteers (completed)

- GS-US-311-0101, a Phase 1 healthy volunteer study evaluating the drug interaction potential between once-daily FTC/GS-7340 fixed-dose combination and efavirenz (EFV) or COBI-boosted darunavir (DRV) (completed)

- GS-US-311-1088, a Phase 1, Relative Bioavailability Study of Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative to co-administration of individual agents (completed)

- GS-US-311-1089, a Phase 3 study of the safety and efficacy of FTC/TAF in HIV-infected, virologically suppressed patients (ongoing).
In Study GS-US-311-1386, the effect of food (high-calorie, high-fat meal) on the PK of the TAF component of the F/TAF FDC was evaluated. The GLSM ratio of the AUC\textsubscript{last} of TAF when administered with a high-fat meal was 177\% (90\% CI: 166\% to 188\%), and the TAF C\text{max} GLSM ratio was 84.5\% (90\% CI: 74.9\% to 95.4\%). This ~75\% increase in TAF plasma exposure and ~15\% decrease in TAF plasma C\text{max} when administered with food was accompanied by a delay in T\text{max} (increase from 1.00 hour under fasted conditions to 2.00 hours under fed conditions). The exposures of TAF observed under fed or fasted conditions in this study are within the range of exposures observed in the E/C/F/TAF clinical development program and are commensurate with safe and effective plasma levels of TAF (see investigator brochure for further details). Therefore, the changes in TAF exposures when F/TAF is administered with food should not result in differences in efficacy and thus are not clinically relevant. TAF can be administered without regard for food and these findings can be extrapolated to F/TAF (as FTC can be taken without regard to food).

1.4.2. \textbf{Clinical Trials of FTC/TAF as part of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)}

Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/TAF STR include:

- GS-US-292-0101, a Phase 1 healthy volunteer study evaluating the relative bioavailability of EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF (completed)
- GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and relative bioavailability of the E/C/F/TAF STR relative to the individual components at GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)
- GS-US-292-0102, a Phase 2 randomized, double-blinded study of the safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, antiretroviral treatment-na\text{ive} adults (ongoing)
- GS-US-292-0109, a Phase 3 open-label study to evaluate switching from a TDF-containing combination regimen to a TAF-containing combination single tablet regimen (STR) in virologically-suppressed, HIV-1 positive subjects (ongoing)
- GS-US-292-0112, a Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single-tablet Regimen in HIV-1 positive patients with mild to moderate renal impairment (ongoing)
- GS-US-292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir Alafenam ide versus placebo added to a failing regimen followed by treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 positive, antiretroviral treatment-experienced adults (ongoing)
• GS-US-292-0119, a Phase 3 open-label study to evaluate switching from optimized stable antiretroviral regimens containing darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive adults (ongoing)

• GS-US-292-0106, a Phase 2/3, open-label study of the pharmacokinetics, safety, and antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive adolescents (ongoing)

Study GS-US-292-0101 is a Phase 1 study of 40 subjects evaluating the relative bioavailability of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolayer or bi-layer). In contrast, TAF exposures were ~2.2-fold higher (and corresponding tenofovir exposures ~ 3-fold higher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mg for both formulations of the E/C/F/TAF, likely mediated by inhibition of Pgp-mediated intestinal secretion of TAF by COBI.

Study GS-US-292-0103 is a completed Phase 1 healthy volunteer study which evaluated the PK and relative bioavailability of the E/C/F/TAF STR relative to the individual components at TAF doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. Exposures of EVG, COBI, and FTC were also comparable between the STR and individually dosed formulations.

Study GS-US-292-0102 is an ongoing, randomized, active-controlled Phase 2 study, compares E/C/F/TAF (10 mg) versus Stribild® (STB, E/C/F/TDF) in treatment-naïve, HIV-1 infected subjects. At Week 48, the E/C/F/TAF demonstrated potent antiviral efficacy (HIV-1 RNA < 50 copies/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components of the E/C/F/TAF. Importantly, E/C/F/TAF demonstrated a potential benefit over E/C/F/TDF in terms of renal and bone safety: smaller median decreases in eGFR (mL/min) (at Week 48, E/C/F/TAF -5.5 vs E/C/F/TDF -10.0 [p<0.001] and smaller median percentage decreases in BMD (at Week 48, spine E/C/F/TAF -1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 vs -2.39 [p<0.001]).

Studies GS-US-292-0104 and GS-US-292-0111 are ongoing, Phase 3 randomized, double-blinded studies of the safety and efficacy of E/C/F/TAF versus E/C/F/TDF in HIV-1 infected, antiretroviral treatment-naive adults. The interim Week 48 key conclusions from pooled data showed that E/C/F/TAF once daily was noninferior to STB once daily when administered for 48 weeks to HIV-infected, ART-naïve adults, as assessed using the US FDA-defined snapshot algorithm with HIV-1 RNA < 50 copies/mL (E/C/F/TAF 92.4%; STB 90.4%; difference in percentages: 2.0%, 95% CI: -0.7% to 4.7%). Administration of E/C/F/TAF resulted
in > 90% lower plasma TFV and higher intracellular TFV-DP relative to STB. E/C/F/TAF showed an improved renal and bone safety profile with significantly less decline in hip and spine BMD, less increase in serum creatinine and reduction in estimated glomerular filtration rate (eGFR).

1.5. Information about GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF)

Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.

1.5.1. GS-US-141-1233: Study of the Relative Bioavailability of GS-9883, FTC, and TAF between GS-9883/F/TAF and GS-9883 + F/TAF

Study GS-US-141-1233 is an ongoing Phase 1, open-label, 2-cohort, multiple-period, fixed-sequence, crossover study conducted at a single center in the US to evaluate 1) the relative bioavailability (BA) of 2 GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets compared with the GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered simultaneously and 2) the effect of food on the PK of GS-9883, FTC, and TAF when administered as GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets.

Cohort 1 evaluated the relative BA and food effect of GS-9883/F/TAF (75/200/25 mg) FDC tablet in a 3-period sequence. Following review of preliminary data from Cohort 1, Cohort 2 was added to the study via protocol amendment. Cohort 2 evaluated the relative BA and food effect of GS-9883/F/TAF (50/200/25 mg) FDC tablet in a 4-period sequence.

The in-life portion of Cohorts 1 and 2 are complete. Preliminary results are summarized below.

**Cohort 1 Results:**

**Pharmacokinetic Results**

Under fasted conditions, GS-9883 AUC_{inf} and C_{max} were 27% and 31% higher, respectively, following GS-9883/F/TAF (75/200/25 mg) FDC administration than following administration of single-agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC. FTC and TAF exposure was similar following administration of GS-9883/F/TAF (75/200/25 mg) or single-agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC.

Compared with administration under fasted conditions, administration of the GS-9883/F/TAF (75/200/25 mg) FDC with a high-fat meal resulted in a 46% higher GS-9883 AUC_{inf} and a 27% higher GS-9883 C_{max}. The impact of food on TAF and FTC exposure was similar to that previously observed for F/TAF (Study GS-US-311-1386). GS-9883/F/TAF may be taken without regard to food. Based on these results, Cohort 2 was added to the study via protocol amendment to evaluate the relative BA of the GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered simultaneously.
Safety Results

Of the 28 subjects included in the Safety Analysis Set for Cohort 1, 12 subjects (43%) had at least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in severity. No deaths or other SAEs occurred during this study, and no subject discontinued the study due to an AE.

Cohort 2 Results:

Pharmacokinetic Results

The PK results from Study GS-US-141-1233 demonstrated that the GS-9883 AUC\textsubscript{\text{inf}} and C\textsubscript{\text{max}} following administration of the 50mg GS-9883 FDC tablets was 79% and 78%, respectively of those observed in the same study following co-administration of GS-9883 75 mg single agent with F/TAF (200/25 mg) under fasted conditions. The GS-9883 exposures of 50 and 75 mg fixed dose combination tablets were approximately dose proportional under fasted and fed conditions, and a high fat and moderate fat meal had similar impact on GS-9883 with AUC\textsubscript{\text{inf}} increasing by 24%. The steady state \(p_{\text{D}}\) of GS-9883/F/TAF (50/200/25 mg) was predicted to be 17 (fasted)-23 (fed). The exposures of TAF and FTC of the 50 mg GS-9883 FDC were similar to those of GS-9883 75 mg single agent with F/TAF FDC, and the food effect on TAF and FTC was similar to the historical results.

Safety Results

Of the 28 subjects included in the Safety Analysis Set for Cohort 2, 12 subjects (43%) had at least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in severity. No deaths or other SAEs occurred during this study, and no subject discontinued the study due to an AE.

1.6. Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC Triumeq®)

For more detailed information, refer to the current Prescribing Information and local product labeling for abacavir/dolutegravir/lamivudine.

1.7. Rationale for this Study

HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic suppression, but nucleos(t)ide-associated toxicities are increasingly important as HIV-infected patients are often diagnosed earlier, initiate therapy earlier, and look toward lifelong therapy (often greater than 50 years). Where patients have access to treatment, morbidity and mortality are driven by non–AIDS-associated comorbidities, which are observed earlier than in HIV-uninfected age-matched controls despite the best available ART. The contribution of specific nucleos(t)ides, including abacavir and tenofovir disoproxil fumarate, to long-term morbidity and mortality is increasingly important in this context.
The GS-9883/F/TAF FDC has the potential to offer a simple, once-daily regimen containing a second generation INSTI that provides a high barrier to resistance, does not require a boosting agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, without the need for HLA testing or close monitoring of renal or bone toxicities. It could provide a FDC treatment that avoids the risk of hypersensitivity reactions, would not contribute to an increased risk of cardiovascular events, could be used in patients with chronic hepatitis B or C infection or renal impairment, and that could be continued as patients age and confront non-HIV-related comorbidities.

The objective of this study is to evaluate the safety and efficacy of a FDC containing GS-9883/F/TAF versus ABC/DTG/3TC. ABC/DTG/3TC was selected as the active comparator for this study as it is a second-generation integrase inhibitor-based, once-daily fixed dose combination, and is a DHHS Guidelines preferred regimen. Use of ABC/DTG/3TC as a comparator in this study will therefore allow comparison of two single tablet regimens containing second generation, unboosted INSTIs.

**1.8. Risk/Benefit Assessment for the Study**

All patients with HIV-1 infection should receive effective anti-retroviral therapy. Potential risks associated with all classes of ARVs include immune reconstitution syndrome, lipodystrophy, and lactic acidosis with steatosis. The risk of class effects is considered to be low. Important identified risks appropriately managed by study inclusion/exclusion criteria as well as through close clinical and laboratory monitoring during the study, are as follows: hypersensitivity reaction to abacavir and allergy to any components of the tablets. Some observational studies have shown increased risk of cardiovascular disease with abacavir. Interim data will also be reviewed by an independent data monitoring committee.

In a study of GS-9883 in monkeys, administration of 1000 mg/kg/day (highest dose) for 39 weeks resulted in histologic findings of bile duct hyperplasia and hepatocyte hypertrophy. No adverse effects were noted at the mid-dose group (200 mg/kg/day), which resulted in exposures of GS-9883 5.1 times higher than the expected human exposure with administration of GS-9883/F/TAF (50/200/25 mg) tablets. No such findings were seen in rats at any dose. However, the risk of liver or biliary abnormalities in humans receiving GS-9883/F/TAF (50/200/25 mg) for chronic use is unknown. Potential hepatobiliary toxicity is appropriately managed by study inclusion/exclusion criteria, close clinical and laboratory monitoring, as well as specific toxicity management guidance to investigators (Refer to Section 7.5.5.).

Potential benefits of GS-9883 may include provision of a new antiretroviral therapy that is not currently available and which may have fewer side effects than alternative therapies. Other potential benefits include provisions of fixed dose combination therapy, and the knowledge that patient participation will contribute to the body of knowledge of HIV therapies.

The overall benefit-risk assessment for GS-9883/F/TAF and ABC/DTG/3TC is favorable at this time.
1.9. Rationale for Dose Selection

FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currently available as single agent capsules (EMTRIVA) and as a component of a number of fixed-dose combination tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRIBILD.

TAF
Based upon results of the Phase 1 Study GS-US-120-0104, in which various doses of TAF (8 mg, 25 mg, and 40 mg) were administered to HIV-infected subjects in 10 days of monotherapy, the range of exposure achieved with TAF 25 mg was chosen as the reference exposure. In this study, TAF 25 mg resulted in near-maximal antiviral activity and plasma TFV exposure > 90% lower relative to TDF.

The recommended dose of TAF is based on ensuring that patients have a TAF systemic exposure that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safety and efficacy database exists. Specifically, TAF 25 mg is recommended with third agents that do not have a clinically relevant effect on TAF exposure. Study GS-US-141-1418 showed that GS-9883 does not have a clinically relevant effect on TAF exposure. Therefore, the dose of TAF 25 mg is appropriate for the GS-9883/F/TAF FDC.

GS-9883
The dose of GS-9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 (Table 1-5), in which HIV-1-infected subjects were administered 5, 25, 50, or 100 mg doses of GS-9883 monotherapy under fasting conditions for 10 days.

Table 1-5. GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values

<table>
<thead>
<tr>
<th>GS-9883 dose</th>
<th>n</th>
<th>Median (range) CtauSS (ng/mL)</th>
<th>Median (range) palIQ95a</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>4</td>
<td>206.5 (146.0 – 342.0)</td>
<td>1.3 (0.9 – 2.1)</td>
</tr>
<tr>
<td>25 mg</td>
<td>4</td>
<td>797.5 (714.0 – 1900.0)</td>
<td>4.9 (4.4 – 11.7)</td>
</tr>
<tr>
<td>50 mg</td>
<td>4</td>
<td>2170.0 (852.0 – 3020.0)</td>
<td>13.4 (5.3 – 18.6)</td>
</tr>
<tr>
<td>100 mg</td>
<td>4</td>
<td>4190.0 (3730.0 – 5970.0)</td>
<td>25.9 (23 – 36.9)</td>
</tr>
</tbody>
</table>

a. The palIQ95 value is estimated based on steady-state Ctau values and the in vitro palIC95 value for wild-type HIV-1 (162 ng/mL).

Source: Data on File
Single-agent GS-9883 was well tolerated at all doses administered. The range of GS-9883 plasma exposure at steady state (C_{tau,SS}) observed in the 50-mg cohort correlated with protein adjusted 95% inhibitory quotient (paIQ_{95}) values ranging from 5.3 to 19, while the range of GS-9883 plasma exposure at steady state (C_{tau,SS}) observed in the 100-mg cohort correlated with paIQ_{95} values ranging from 23 to 37 (Table 1-5).

Based on PK/PD analyses, exposure following a 75-mg dose of single-agent GS-9883 is expected to provide near-maximal virologic response, with a predicted paIQ_{95} of approximately 20, providing considerable coverage above the target concentration of 162 ng/mL (paIC_{95}). GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currently being evaluated in a Phase 2 study, GS-US-141-1475 (GS-9883+F/TAF vs DTG+F/TAF). The Week 24 data from this study support the safety and efficacy of GS-9883 exposures obtained with the 75 mg dose of the single agent.

**GS-9883/F/TAF FDC Dose Selection**

A fixed dose formulation of GS-9883/F/TAF was developed for use in Phase 3 studies. Preliminary results from the relative bioavailability (rBA) study (GS-US-141-1233) of GS-9883/F/TAF (75/200/25 mg) showed that GS-9883 plasma exposure was higher (with C_{max} and AUC_{inf} increase of 31% and 27%, respectively) following administration of the FDC as compared with exposure following administration of GS-9883 (75 mg) + F/TAF (200/25 mg) under fasted conditions. The increase in GS-9883 exposures associated with the FDC formulation results in an estimated mean paIQ_{95} of 24.3, compared to an estimated mean paIQ_{95} of 19.2 for the GS-9883 (75 mg) single agent coadministered with F/TAF, in the fasted state.

In order to bridge exposures of GS-9883 in the FDC to the exposure observed with GS-9883 75 mg administered as a single agent, and to bridge to the safe and effective exposures observed in the Phase 2 study GS-US-141-1475, a lower strength GS-9883/F/TAF FDC was developed for use in the Phase 3 studies. Comparability of GS-9883 exposures was confirmed in an rBA study of GS-9883/F/TAF (50/200/25 mg) and GS-9883 (75 mg) + F/TAF prior to initiation of dosing in the Phase 3 studies.

**1.10. Compliance**

This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), and all applicable regulatory requirements.
2. OBJECTIVES

The primary objective of this study is:

- To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naïve-adult subjects as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 48

The secondary objectives of this study are:

- To evaluate the efficacy, safety, and tolerability of the two treatment groups through Weeks 48 and 96
- To evaluate the bone safety of the two treatment groups as determined by the percentage change from baseline in hip and spine BMD through Weeks 48 and Week 96
3. STUDY DESIGN

3.1. Endpoints

The primary endpoint is:

- the proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm

The secondary endpoints of this study include:

- the proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 as defined by the US FDA-defined snapshot algorithm
- the proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 as defined by the US FDA-defined snapshot algorithm
- the change from baseline in log_{10} HIV-1 RNA and CD4+ cell count at Weeks 48 and 96
- the percentage change from baseline in hip and spine BMD at Weeks 48 and 96

3.2. Study Design

This protocol describes a randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of GS-9883/F/TAF FDC versus ABC/DTG/3TC FDC in HIV-1 infected, antiretroviral treatment-naïve adult subjects.

3.3. Study Treatments

Subjects who provide written informed consent and meet all eligibility criteria will be randomized in a 1:1 ratio to one of the following two treatment groups:

**Treatment Group 1:** FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to food (n=300)

**Treatment Group 2:** FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food (n=300)

Randomization will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL, > 100,000 to ≤ 400,000 copies/mL, or > 400,000 copies/mL) at screening, CD4+ cell count (< 50 cells/μL, 50 – 199 cells/μL, or ≥ 200 cells/μL) at screening, and region (US vs. Ex-US) at randomization.
3.4. Duration of Treatment

Subjects will be treated for at least 96 weeks. Subjects’ treatments will be unblinded after the last subject completes the Week 96 visit and Gilead completes the Week 96 analysis. Subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. At the Unblinding Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

Figure 3-1. Study Schema

```
| Screening | Treatment Group 1: GS-9883/F/TAF FDC QD + Placebo to match ABC/DTG/3TC FDC QD (N=300) |
| Day 1     | Treatment Group 2: ABC/DTG/3TC FDC QD + Placebo to match GS-9883/FTC/TAF FDC QD (N=300) |
| Week 48^b | Unblinding^d |
| Week 96^b | 30 Day F/U   |
```

a Following the Day 1 visit, subjects will be required to return for study visits at Weeks 4, 8, 12, and then every 12 weeks through Week 96.

b After Week 96, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. Subjects’ treatments will be unblinded after the last subject completes the Week 96 visit and Gilead completes the Week 96 analysis.

c Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects will return to the clinic (preferably within 30 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

d Subjects who complete the study through the Unblinding Visit and do not continue on the open-label GS-9883/F/TAF FDC extension phase will be required to return to the clinic 30 days after the completion of study drugs for a 30-Day Follow-Up Visit

3.5. Biomarker Testing

3.5.1. Biomarker Samples for Optional Pharmacogenomic Research

PPD
3.5.2. Additional Sample Storage

For subjects who provide additional consent, residual blood and urine samples taken throughout the study will be stored. Stored samples may be used by the Sponsor or its research partners to help answer questions about the study drug, and HIV disease and its associated conditions, or to provide additional safety data. At the conclusion of this study, these samples may be retained in storage by Gilead Sciences for a period up to 15 years.
4. SUBJECT POPULATION

4.1. Number of Subjects and Subject Selection

Approximately 600 subjects who meet the eligibility criteria will be enrolled.

4.2. Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.

1) The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures

2) Age ≥ 18 years

3) Antiretroviral treatment naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for PrEP (pre-exposure prophylaxis) or PEP (post-exposure prophylaxis), up to one month prior to screening

4) Plasma HIV-1 RNA levels ≥ 500 copies/mL at screening

5) Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)

6) Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec) according to the Cockcroft-Gault formula \{Cockcroft et al 1976\}:

i) Male: \[
\frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72} \times (\text{serum creatinine in mg/dL}) = \text{CLcr (mL/min)}
\]

\[
\frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72 \times (\text{serum creatinine in umol/L})} \times 0.6786 = \text{CLcr (mL/sec)}
\]

ii) Female: \[
\frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72} \times (\text{serum creatinine in mg/dL}) = \text{CLcr (mL/min)}
\]

\[
\frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72 \times (\text{serum creatinine in umol/L}) \times 0.6786} = \text{CLcr (mL/sec)}
\]

7) Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)

8) Total bilirubin ≤ 1.5 mg/dL (≤ 26 umol/L), or normal direct bilirubin
9) Adequate hematologic function (absolute neutrophil count ≥ 750/mm$^3$ (≥ 0.75 GI/L); platelets ≥ 50,000/mm$^3$ (≥ 50 GI/L); hemoglobin ≥ 8.5 g/dL (≥ 85 g/L))

10) Serum amylase ≤ 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if serum lipase is ≤ 5 × ULN)

11) Females of childbearing potential must agree to utilize protocol recommended highly effective contraceptive methods or be non-heterosexually active or practice sexual abstinence (as defined in Appendix 6) from screening, throughout the duration of the study period, and for 30 days following the last dose of study drug.

   a) Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least 3 months prior to study drug dosing.

12) Male subjects who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception (as described in Appendix 6) throughout the study period and for 90 days following the last dose of study drug

13) Male subjects must agree to refrain from sperm donation from first study drug dose until at least 90 days following the last study drug dose

14) Life expectancy ≥ 1 year

15) Screening genotype report must show sensitivity to FTC, TFV, 3TC, and ABC. This report will be provided by Gilead Sciences. Alternatively, if genotype results from a local laboratory obtained ≤ 90 days prior to screening visit date show sensitivity to these drugs, this genotype will be acceptable to fulfill this inclusion criterion in the event that the genotype obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed.

16) Negative screening test for HLA-B*5701 allele provided by Gilead Sciences. Alternatively, if HLA-B*5701 results are available from a local laboratory prior to screening, this report will be acceptable to fulfill this inclusion criterion in the event that the HLA-B*5701 result obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed.

4.3. Exclusion Criteria

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.

17) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening (refer to Appendix 5)

18) Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, or variceal bleeding)
19) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)

20) Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance

21) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Day 1 and are not anticipated to require systemic therapy during the study

22) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1

23) Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial

24) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements

25) Any known allergies to the excipients of GS-9883/F/TAF FDC or ABC/DTG/3TC FDC tablets

26) Females who are pregnant (as confirmed by positive serum pregnancy test)

27) Females who are breastfeeding

28) Subjects receiving ongoing therapy with any of the following medications in the table below, including drugs not to be used with FTC, TAF, GS-9883, DTG, ABC and 3TC

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Agents Disallowed*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmic Agent</td>
<td>Dofetilide</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine</td>
</tr>
<tr>
<td>Antimycobacterials</td>
<td>Rifampin, Rifapentine</td>
</tr>
<tr>
<td>Antiretrovirals</td>
<td>Any antiretroviral drug that is not part of the study regimen</td>
</tr>
<tr>
<td>GI Motility Agents</td>
<td>Cisapride</td>
</tr>
<tr>
<td>Herbal/Natural Supplements</td>
<td>St. John’s Wort, Echinacea</td>
</tr>
</tbody>
</table>

* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the duration of the study.

29) Acute hepatitis in the 30 days prior to study entry
30) Chronic Hepatitis B Virus (HBV) infection, as determined by either:

   a) Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit

   b) Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit

31) Active tuberculosis infection
5. INVESTIGATIONAL MEDICINAL PRODUCTS

5.1. Randomization, Blinding and Treatment Codes

Subjects will be assigned a screening number at the time of consent. Randomization and Day 1 visits cannot occur until the Investigator has received the results of the allele testing and screening genotype report and subject eligibility has been confirmed.

Once eligibility has been confirmed and prior to or during the Day1 visit, the Investigator or designee will randomize the subject using the Interactive Web Response System (IWRS). Once a subject number has been assigned to a subject, it will not be reassigned to any other subject. The subject number assignment and randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been confirmed.

Subjects will be randomized in a 1:1 ratio to Treatment Group 1 or Treatment Group 2.

Randomization will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL, > 100,000 to ≤ 400,000 copies/mL, or > 400,000 copies/mL) at screening, CD4+ cell count (< 50 cells/μL, 50 – 199 cells/μL, or ≥ 200 cells/μL) at screening and region (US vs. Ex-US) at randomization.

The IWRS will assign study drug bottle numbers of blinded FDC of GS-9883/F/TAF + Placebo to match FDC of ABC/DTG/3TC or FDC of ABC/DTG/3TC + Placebo to match FDC of GS-9883/F/TAF at each study visit for each subject.

5.1.1. Procedures for Breaking Treatment Codes

In the event of a medical emergency where breaking the blind is required to provide medical care to the subject, the investigator may obtain treatment assignment directly from the IWRS system for that subject. Gilead strongly recommends but does not require that the investigator contact the Gilead medical monitor before breaking the blind. Treatment assignment should remain blinded unless that knowledge is necessary to determine subject emergency medical care. The rationale for unblinding must be clearly explained in source documentation and on the electronic case report form (eCRF), along with the date on which the treatment assignment was obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of any treatment unblinding.

Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a subject’s treatment assignment is disclosed to the investigator, the subject will have study treatment discontinued. All subjects will be followed until study completion unless consent to do so is specifically withdrawn by the subject.

Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited reporting of suspected unexpected serious adverse reactions (SUSARs).
5.2. Description and Handling

5.2.1. Formulation

5.2.1.1. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF)
50 mg/200 mg/25 mg and Placebo to Match Tablets

GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule-shaped, film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side of the tablet. Each tablet core contains 50 mg of GS-9883, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the GS-9883/F/TAF tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

The placebo to match (PTM) GS-9883/F/TAF tablets are capsule-shaped, film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side and are identical in physical appearance to GS-9883/F/TAF tablets. The placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

5.2.1.2. Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®)
600 mg/50 mg/300 mg and Placebo to Match Tablets

Abacavir 600 mg/Dolutegravir 50 mg/Lamivudine 300 mg tablets are oval, film coated purple, and debossed with “572 Tri” on one side. Each tablet core contains 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. In addition to the active ingredients, the ABC/DTG/3TC tablets contain the inactive ingredients D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet cores are film coated with iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and titanium oxide.

The PTM ABC/DTG/3TC tablets are oval, film coated purple, and debossed with “572 Tri” on one side. The placebo tablets are identical in physical appearance to ABC/DTG/3TC tablets. The placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The tablet cores are film-coated with iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and titanium oxide.

5.2.2. Packaging and Labeling

5.2.2.1. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF)
50 mg/200 mg/25 mg and Placebo to Match Tablets

GS-9883/F/TAF tablets and PTM GS-9883/F/TAF tablets are packaged in white, high density polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and polyester packing material. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.2.2. Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®)
600 mg/50 mg/300 mg and Placebo to Match Tablets

ABC/DTG/3TC tablets and PTM ABC/DTG/3TC tablets are packaged in white, high density polyethylene (HDPE) bottles. Each bottle contains 30 tablets and silica gel desiccant. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.

Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.3. Storage and Handling

Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both FDCs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, accessible only to authorized site personnel.

To ensure the stability and proper identification, study drug(s) should not be stored in a container other than the container in which they were supplied.

Consideration should be given to handling, preparation, and disposal through measures that minimize drug contact with the body. Appropriate precautions should be followed to avoid direct eye contact or exposure through inhalation when handling.

5.3. Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide and Abacavir/Dolutegravir/Lamivudine

Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both FDCs will be provided by Gilead Sciences.

**Treatment Group 1:** FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to food

**Treatment Group 2:** FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food. Subjects will be instructed to bring all study medication in the original container at each clinic visit for drug accountability. The Investigator will be responsible for maintaining accurate
records for all study drug bottles dispensed and tablets returned. The inventory and dispensing
logs must be available for inspection by the study monitor. Study medication supplies, including
partially used or empty bottles, must be accounted for by the study monitor prior to destruction
or return.

5.4. Prior and Concomitant Medications

- The use of medications for the treatment of HIV, other than study drug, is prohibited.

- Medications listed in the following table and use of herbal/natural supplements are excluded
  or should be used with caution while subjects are participating in the study. Subjects will
  refrain from consumption of grapefruit juice and Seville orange juice throughout
  participation in the study.

<table>
<thead>
<tr>
<th>Table 5-1. Prior and Concomitant Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Class</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Acid Reducing Agents</td>
</tr>
<tr>
<td>Antiarrhythmic Agent</td>
</tr>
<tr>
<td>Anticonvulsants</td>
</tr>
<tr>
<td>Antimycobacterials</td>
</tr>
<tr>
<td>Antiretrovirals</td>
</tr>
<tr>
<td>GI Motility Agents</td>
</tr>
<tr>
<td>Herbal/Natural Supplements</td>
</tr>
<tr>
<td>Oral Hypoglycemic Agent</td>
</tr>
</tbody>
</table>

* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the duration of the study.
Should subjects have a need to initiate treatment with any excluded concomitant medication, the Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In instances where an excluded medication is initiated prior to discussion with the Sponsor, the Investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded medication.

5.5. Accountability for Investigational Medicinal Product (IMP)

The investigator is responsible for ensuring adequate accountability of all used and unused IMP. This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All used and unused IMP dispensed to subjects must be returned to the site.

Study Drug accountability records will be provided to each study site to:

- Record the date received and quantity of IMP kits
- Record the date, subject number, subject initials, the IMP kit number dispensed
- Record the date, quantity of used and unused IMP returned, along with the initials of the person recording the information

5.5.1. Investigational Medicinal Product Return or Disposal

Study drug return and disposal will be performed as outlined in Section 9.1.7.
6. STUDY PROCEDURES

The study procedures to be conducted for each subject enrolled in the study are presented in tabular form in Appendix 2 and described in the text that follows.

The investigator must document any deviation from protocol procedures and notify the sponsor or contract research organization (CRO).

6.1. Subject Enrollment and Treatment Assignment

It is the responsibility of the Investigator to ensure that subjects are eligible for study prior to enrollment. Please refer to Section 6.3 for details about randomization and treatment assignment.

6.2. Pretreatment Assessments

6.2.1. Screening Visit

Subjects will be screened within 30-days before Day 1 to determine eligibility for participation in the study. The following will be performed and documented at screening:

- Obtain written informed consent
- Obtain medical history including history of HIV-1 disease-related events, smoking history and prior medications within 30 days of the screening visit
- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)
- 12-lead ECG performed supine
- Height
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Urine collection for the following laboratory procedures:
  - Urinalysis
- Blood sample collection for the following laboratory analyses:
  - Serum pregnancy test (females of childbearing potential only). If the test is positive, the subject will not be enrolled
  - Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN) and TSH.
— Estimated glomerular filtration rate according to the Cockcroft-Gault formula:

Male:  
\[
\text{CLcr (mL/min)} = \frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72 \times (\text{serum creatinine in mg/dL})} \\
\text{CLcr (mL/sec)} = \frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72 \times (\text{serum creatinine in umol/L}) \times 0.6786}
\]

Female:  
\[
\text{CLcr (mL/min)} = \frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72 \times (\text{serum creatinine in mg/dL})} \\
\text{CLcr (mL/sec)} = \frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72 \times (\text{serum creatinine in umol/L}) \times 0.6786}
\]

— Hematology profile: complete blood count (CBC) with differential and platelet count
— CD4+ cell count
— HLA-B*5701
— Plasma HIV-1 RNA
— Hepatitis B virus surface antigen serology (HBsAg)
— Hepatitis B surface antibody (HBsAb)
— Hepatitis B virus core antibody (HBcAb)
— Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a HCV RNA test performed.
— HIV-1 genotype testing (protease and reverse transcriptase). The HIV-1 PR/RT genotype testing may not be performed for subjects that fail to meet other screening criteria.

• Review of adverse events and concomitant medications

Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the clinic within 30-days after screening for the Day 1 visit.

From the time of obtaining informed consent through the first administration of investigational medicinal product, record all serious adverse events (SAEs), as well as any adverse events related to protocol-mandated procedures on the adverse events case report form (eCRF). All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical history are to be captured on the medical history eCRF. See Section 7 Adverse Events and Toxicity Management for additional details.
6.2.2. **Day 1 Assessments**

The following evaluations are to be completed at the Day 1 Visit. **The Investigator must have received the results from the allele testing and screening genotype report and confirmed eligibility before proceeding with the Day 1 visit.** The subject must complete all study procedures, except DXA, before being administered the study drug:

- DXA Scan (spine and hip). For subjects in Germany, DXA scans will not be performed.
  - The DXA scan will be performed on subjects once eligibility is confirmed. The scan may be performed prior to or within 24 hours of the Day 1 Visit.
- Review of AEs and changes in concomitant medications
- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- 12-lead ECG performed supine
- Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) to be completed by the subject. Subject is to read questionnaire by himself/herself and write/mark answers directly onto questionnaires.
- Urine collection for the following laboratory procedures:
  - Urinalysis
  - Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2-microglobulin
  - Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test. If the test is positive, the subject will not be able to participate
  - Urine storage sample for possible additional clinical testing
- Blood sample collection for the following laboratory analyses:
  - Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN) and TSH
— Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.

— Estimated glomerular filtration rate according to the Cockcroft-Gault formula

— Hematology profile: complete blood count (CBC) with differential and platelet count

— Plasma HIV-1 RNA

— CD4+ cell count

— Evaluations of inflammation and immune activation, may include but not limited to cystatin-C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163

— Evaluations of platelet function, may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand

— Plasma storage sample for safety, virology, or PK testing

• Optional Peripheral Blood Mononuclear cell (PBMC) Substudy:

• Optional blood sample collection for the following laboratory analyses if pharmacogenomic consent is obtained
6.3. Randomization

Once eligibility has been confirmed and prior to or during the Day 1 visit, the Investigator or designee will randomize the subject using the Interactive Web Response System (IWRS). Once a subject number has been assigned to a subject, it will not be reassigned to any other subject. The subject number assignment and randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been confirmed.

6.4. Treatment Assessments (Week 4 - 96)

The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 unless otherwise specified.

Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days of the protocol-specified visit date through Week 96, unless otherwise specified. The visit window at Weeks 48 and 96 will be ± 6 weeks of the protocol-specified visit date, and these clinical visit windows coincide with the Week 48 and Week 96 statistical analysis window for HIV-1 RNA.

Regularly scheduled evaluations will be made on all subjects whether or not they continue to receive study drug.

- Review of AEs and changes in concomitant medications
- DXA scans (spine and hip) for all subjects who are on study drug (Weeks 24, 48 and 96 ±10 days). For subjects in Germany, DXA scans will not be performed.
- Complete physical examination (Weeks 24 and 48) (urogenital/anorectal exams will be performed at the discretion of the Investigator) or symptom-directed physical examination as needed
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- 12-lead ECG performed supine (Weeks 24 and 48)
- Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) to be completed by the subject at Weeks 4, 12 and 48. Subject is to read questionnaire by himself/herself and write/make answers directly onto questionnaires.
- Urine collection for the following laboratory procedures:
  - Urinalysis
  - Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2-microglobulin. (Weeks 24, 48, 72 and 96)
— Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test. If the test is positive, the subject will be discontinued.

— Urine storage sample for possible additional clinical testing.

- Blood sample collection for the following laboratory analyses:

  — Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN). At Weeks 12, 24, 48, 72 and 96 analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry profile. At Weeks 24, 48, 72 and 96 TSH will also be analyzed.

  — Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments. (Weeks 12, 24, 48, 72 and 96)

  — Estimated glomerular filtration rate according to the Cockcroft-Gault formula

  — Hematology profile: complete blood count (CBC) with differential and platelet count

  — Plasma HIV-1 RNA

  — CD4+ cell count

  — Evaluations of inflammation and immune activation, may include but not limited to cystatin-C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Weeks 24, 48, 72 and 96)

  — Evaluations of platelet function, may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand (Weeks 24, 48, 72 and 96)

  — Plasma storage sample for safety, virology, or PK testing

- Pharmacokinetic Blood Collection for subjects who are on study drug. Details of pharmacokinetic blood sampling procedures and sample management will be documented in the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment Manual.

  — Single Anytime, Trough and Post Dose PK Samples for all subjects on study drug:

    ■ Subjects will have a single anytime pre or post-dose PK blood at Weeks 8, 24 and 36.
• Observed dosing at the clinic: Subjects will have a trough PK blood sample collected between 20-28 hours following their last dose at Weeks 4 and 12. Subjects must be instructed to not take their study drugs on the morning of their visit for the trough sample collection. Subjects will then take an observed dose of study drug at the clinic. A single post dose PK blood sample will be collected between 1 and 4 hours post dose. If the subject has taken their dose of study drugs prior to the visit, the visit may proceed, but the subject must return within 72 hours for the trough PK blood sample collection. In the event a subject routinely takes their study drug in the evening, a single post dose sample may be drawn at Weeks 4 and 12 as the subject will not be instructed to change their dosing time to accommodate this trough PK draw.

• Dosing diaries will be collected from subjects for the single anytime PK and trough PK collection. If a dosing diary is not returned the site may ask the subject for the time of the last dose and if it was taken with or without food.

— Optional Pharmacokinetic (PK) Substudy:

• Optional Peripheral Blood Mononuclear cell (PBMC) Substudy:
6.5. Treatment Assessments (Post Week 96 until the Unblinding Visit)

6.5.1. Post Week 96 Assessments

After Week 96, subjects will continue to take their blinded study drugs and attend visits every 12 weeks until treatment assignments have been unblinded, at which point they will return for an Unblinding Visit (refer to Section 6.5.2). Study visits are to be completed within ± 6 days of the protocol-specified visit date unless otherwise specified.

- Review of AEs and changes in concomitant medications
- Symptom-directed physical examination as needed
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Urine collection for the following laboratory procedures:
  - Urinalysis
  - Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2-microglobulin (Every 24 weeks)
  - Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test. If the test is positive, the subject will be discontinued.
  - Urine storage sample for possible additional clinical testing
- Blood sample collection for the following laboratory analyses:
  - Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN). Every 24 weeks, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry profile. In addition, TSH will also be analyzed every 24 weeks
  - Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments. (Every 24 weeks)
  - Estimated glomerular filtration rate according to the Cockcroft-Gault formula
— Hematology profile: complete blood count (CBC) with differential and platelet count
— Plasma HIV-1 RNA
— CD4+ cell count
— Evaluations of inflammation and immune activation, may include but not limited to cystatin-C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Every 24 weeks)
— Evaluations of platelet function, may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand (Every 24 weeks)
— Plasma storage sample for safety, virology, or PK testing

• Subjects who meet the criteria for virologic failure will be managed according to the Management of Virologic Rebound Section 6.14.1 and 6.14.2.

• Document study drug dispensation and accountability for all study drugs dispensed.

6.5.2. Unblinding Visit

Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects will return to the clinic (within 30 days ± 6 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

Subjects who receive the open-label GS-9883/F/TAF FDC will return for study visits every 12 weeks.

• Subjects who choose to not receive the open label GS-9883/F/TAF FDC will be required to return to the clinic for a 30-Day Follow-up visit following the Unblinding Visit. Subjects who have discontinued drug study prior to the Unblinding Visit will not be eligible for the open-label rollover extension; these subjects will be asked to continue attending the scheduled study visits through the Unblinding Visit and discontinue the study after the Unblinding Visit.

The following will be performed at the Unblinding Visit:

• Review of AEs and changes in concomitant medications
• DXA scans (spine and hip) for all subjects who are on study drug (±10 days). For subjects in Germany, DXA scans will not be performed.
- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)

- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight

- 12-lead ECG performed supine

- Urine collection for the following laboratory procedures:
  - Urinalysis
  - Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2-microglobulin.
  - Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test. If the test is positive, the subject will not be able to participate.
  - Urine storage sample for possible additional clinical testing

- Blood sample collection for the following laboratory analyses:
  - Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN), and TSH
  - Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments
  - Estimated glomerular filtration rate according to the Cockcroft-Gault formula
  - Hematology profile: complete blood count (CBC) with differential and platelet count
  - Plasma HIV-1 RNA
  - CD4+ cell count
  - Evaluations of inflammation and immune activation, may include but not limited to cystatin-C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163
  - Evaluations of platelet function, may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand
  - Plasma storage sample for safety, virology, or PK testing
• Document study drug dispensation, if applicable and accountability for all study drugs dispensed

• Subjects who wish to continue in the Open-Label Rollover extension study will receive open label GS-9883/F/TAF.

6.6. Post-treatment Assessments

6.6.1. Early Study Drugs Discontinuation Assessments

If the subject discontinues study drug prior to the Unblinding Visit, the subject will be asked to return to the clinic within 72 hours of stopping study drugs for the Early Study Drugs Discontinuation Visit. The subject will be asked to continue attending the scheduled study visits through the Unblinding Visit.

At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results indicating that there is a possible or probable causal relationship with the study drug, will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained.

The following evaluations are to be completed at the Early Study Drugs Discontinuation Visit:

• Review of AEs and changes in concomitant medications

• DXA scan required (spine and hip) for all subjects who are on study drug (±10 days) if last scan was acquired > 12 weeks from the date of the ESDD Visit. For subjects in Germany, DXA scans will not be performed.

• Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)

• 12-lead ECG performed supine

• Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight

• Urine collection for the following laboratory procedures:
  — Urinalysis
  — Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test
  — Urine storage sample for possible additional clinical testing
• Blood sample collection for the following laboratory analyses:
  — Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN), and TSH
  — Estimated glomerular filtration rate according to the Cockcroft-Gault formula
  — Hematology profile: complete blood count (CBC) with differential and platelet count
  — Plasma HIV-1 RNA
  — CD4+ cell count
  — Plasma storage sample for safety, virology, or PK testing
  — HIV-1 genotype/phenotype testing for subjects with virologic failure

• Drug accountability

6.6.2. 30 Day Follow Up

Subjects who complete the study through the Unblinding visit and who do not participate in the open-label rollover extension, will be required to return to the clinic 30 days after the completion of study drug for the 30 Day Follow Up visit.

Subjects who permanently discontinue study drug during the blinded phase and refuse to continue in the study through the Unblinding Visit will be asked to return to the clinic 30 days after the completion of the Early Study Drugs Discontinuation Visit for the 30-Day Follow-Up Visit.

Those subjects who permanently discontinue study drug and continue in the study through at least one subsequent visit after the Early Study Drug Discontinuation Visit will not be required to complete the 30-Day Follow-Up Visit.

For the purpose of scheduling a 30-Day Follow-Up Visit, a ± 6 days window may be used. The following evaluations are to be completed at the 30-Day Follow-Up Visit:

• Review of AEs and changes in concomitant medications

• Symptom-directed physical examination

• Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
• Urine collection for the following laboratory procedures:
  — Urinalysis
  — Urine pregnancy test (females of childbearing potential only); positive urine pregnancy tests will be confirmed with a serum test.

• Blood sample collection for the following laboratory analyses:
  — Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN).
  — Estimated glomerular filtration rate according to the Cockcroft-Gault formula
  — Hematology profile: complete blood count (CBC) with differential and platelet count
  — Plasma HIV-1 RNA
  — CD4+ cell count

At the 30-Day Follow-Up Visit, any evaluations showing abnormal results believed to be a reasonable possibility of a causal relationship with the study drugs will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to baseline, or is otherwise explained.

6.7. Criteria for Discontinuation of Study Treatment

Study medication will be discontinued in the following instances:

• Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the ability to continue study-specific procedures or is considered to not be in the subject’s best interest

• Subject request to discontinue for any reason

• Pregnancy during the study; refer to Appendix 6

• Development of active tuberculosis infection

Study medication may be discontinued in the following instances:

• Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree. Following resolution of intercurrent illness, the subject may resume study dosing at the discretion of the investigator
• Lack of efficacy

• Subject noncompliance

• Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional review board or independent ethics committee (IRB/IEC)

6.8. Bone Mineral Density Evaluations

For all subjects who are on study drug, excluding those enrolled in sites based in Germany, dual energy x-ray absorptiometry (DXA) scans will be performed prior to or within 24 hours of Day 1, Weeks 24, 48, 96, Unblinding Visit and the Early Study Drug Discontinuation Visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit). Scans will cover the spine and hip to measure changes in bone mineral density. DXA scan results will be provided to study sites.

A complete description of the procedures performed for the DXA scans will be provided in a DXA manual.

6.9. Other Evaluations

6.9.1. Markers of Renal Tubular Function

For all subjects, urine will be collected for selected evaluations of renal tubular function, which will include urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2-microglobulin at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48 and the Unblinding Visit.

6.9.2. Markers of Inflammation and Immune Activation

For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48 and the Unblinding Visit for selected evaluations of inflammation and immune activation, which may include but not limited to cystatin-C, IL 6, hs CRP, d-dimer, sCD14, and sCD163.

6.9.3. Markers of Platelet Function

For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48 and the Unblinding Visit for selected evaluations of platelet function, which may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand.

6.10. Blood and Urine Storage

A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30-day follow-up Visit and Unscheduled Visits) will be frozen and stored. These stored blood and urine samples may be used by the Sponsor or its research partners for HIV-1 genotyping/phenotyping assays or their development, for retesting the amount of HIV-1 in the blood, for measurement of
antiviral drug levels in the blood, or for testing to learn more about how the study drug has worked against HIV-1 or clinical laboratory testing to provide additional safety data. No human genetic testing will be performed without expressed consent of study subjects. At the conclusion of this study, these samples may be retained in storage by Gilead Sciences for a period up to 15 years.

6.11. Assessments for Premature Discontinuation from Study

If a subject discontinues study dosing (for example, as a result of an AE), every attempt should be made to keep the subject in the study and continue to perform the required study-related follow-up and procedures (see Section 6.7, Criteria for Discontinuation of Study Treatment). If this is not possible or acceptable to the subject or investigator, the subject may be withdrawn from the study.

6.12. End of Study

The end of study will be the last patient’s last observation (or visit).

6.13. Post Study Care

After a subject has completed/terminated their participation in the study, long-term care for the subject will remain the responsibility of their primary treating physician.

6.14. Virologic Failure

Virologic failure is defined as virologic rebound or having HIV-1 RNA ≥ 50 copies/mL at study drug discontinuation, Week 48 or Week 96.


Subjects who meet the criteria listed below will be considered to have virologic rebound:

- At any visit, after achieving HIV-1 RNA < 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit; OR
- At any visit, a > 1 log_{10} increase in HIV-1 RNA from the nadir which is subsequently confirmed at the following scheduled or unscheduled visit

Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is confirmed at the scheduled or unscheduled visit and the HIV-1 RNA is ≥ 200 copies/mL, the blood sample from the confirmation visit will be the primary sample used for HIV-1 genotypic and phenotypic testing. Subjects with documented non-adherence within 72 hours of the visit may not be tested for resistance. After a subject’s first post-baseline resistance test, additional testing will be conducted on a case-by-case basis. Any subject may be discontinued at Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genotype or phenotype, the subject may remain on study drugs and a repeat HIV-1 RNA should be repeated (2 to 3 weeks after date of test with HIV-1 RNA $\geq 50$ copies/mL). Investigators should carefully evaluate the benefits and risks of remaining on study drug for each individual subject and document this assessment in the on-site medical record.

Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue study drugs for an individual subject must discuss with the Medical Monitor prior to study drug discontinuation.

For subjects who are off study drug but remain on study, it will be the Investigator’s discretion to manage virologic rebound.

Please refer to Figure 6-1 for the management of subjects who meet the criteria for virologic rebound.
Figure 6-1. Virologic Rebound Schema

<table>
<thead>
<tr>
<th>Screening</th>
<th>Treatment Period</th>
<th>30-Day Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>At any visit, after achieving HIV-1 RNA &lt; 50 copies/mL, a rebound in HIV-1 RNA to ≥ 50 copies/mL OR &gt; 1 log_{10} increase in HIV-1 RNA from their nadir</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unconfirmed virologic rebound: remain on current regimen a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Return for scheduled/unscheduled HIV-1 RNA and potential genotype/phenotype sampling (2-3 weeks later)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Confirmed virologic rebound and HIV-1 genotype and phenotype b,c</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If no reverse transcriptase or integrase resistance detected, may continue on study drugs d</td>
<td>Remain on study</td>
</tr>
<tr>
<td></td>
<td>If reverse transcriptase or integrase resistance detected, discontinue study drugs and construct a new ARV regimen e</td>
<td></td>
</tr>
</tbody>
</table>

---

a. If virologic rebound is not confirmed, the subject will remain on their current regimen.
b. If virologic rebound is confirmed and the HIV-1 RNA is ≥ 200 copies/mL, the HIV-1 genotype and phenotype (reverse transcriptase, protease and integrase) will be analyzed.
c. Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be discontinued. If genotyping or phenotyping assay fails, a new ARV regimen may be configured at the discretion of the Investigator.
d. If no resistance is detected, HIV-1 RNA will be repeated (2-3 weeks later). Investigator reviews study drug continuation/discontinuation options and discusses with the Medical Monitor prior to study drug discontinuation.
e. A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.

6.14.2. Subjects with HIV-1 RNA ≥ 50 copies/mL at Study Discontinuation, Week 48 or Week 96

Subjects with HIV-1 RNA ≥ 50 copies/mL at study discontinuation or last visit will be considered virologic failures. Subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 or Week 96 will be asked to return for an unscheduled visit within the visit window for a retest.

Subjects with HIV-1 RNA ≥ 200 copies/mL at study drug discontinuation, last visit, Week 48, or Week 96 will also have resistance testing conducted.
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT

7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events

7.1.1. Adverse Events

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also include pre- or post-treatment complications that occur as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increase in severity or change in nature during or as a consequence of participation in the clinical study will also be considered AEs.

An AE does not include the following:

- Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. The condition that led to the procedure may be an adverse event and must be reported.
- Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the screening visit that do not worsen
- Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for elective surgery, social and/or convenience admissions)
- Overdose without clinical sequelae (see Section 7.6.1)
- Any medical condition or clinically significant laboratory abnormality with an onset date before the consent form is signed and not related to a protocol-associated procedure is not an AE. It is considered to be pre-existing and should be documented on the medical history eCRF.

7.1.2. Serious Adverse Events

A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

- Death
- Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
- In-patient hospitalization or prolongation of existing hospitalization
• Persistent or significant disability/incapacity

• A congenital anomaly/birth defect

• A medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. Medical and scientific judgment must be exercised to determine whether such an event is a reportable under expedited reporting rules. Examples of medically important events include intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; and development of drug dependency or drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal product will be considered a medically important event and subject to expedited reporting requirements.

7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events

Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that require medical or surgical intervention or lead to IMP interruption, modification, or discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the laboratory result (ie, decreased hemoglobin).

For specific information on handling of clinical laboratory abnormalities in this study, please refer to Section 7.5.

7.2. Assessment of Adverse Events and Serious Adverse Events

The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for causality and severity, and for final review and confirmation of accuracy of event information and assessments.

7.2.1. Assessment of Causality for Study Drugs and Procedures

The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP therapy using clinical judgment and the following considerations:

• No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an alternative causality must be provided (eg, pre-existing condition, underlying disease, intercurrent illness, or concomitant medication).

• Yes: There is reasonable possibility that the event may have been caused by the investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causally related in the context of adverse event reporting.

The relationship to study procedures (e.g., invasive procedures such as venipuncture or biopsy) should be assessed using the following considerations:

- **No**: Evidence exists that the adverse event has an etiology other than the study procedure.
- **Yes**: The adverse event occurred as a result of protocol procedures, (e.g., venipuncture)

### 7.2.2. Assessment of Severity

AE severity should be recorded and graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 4). For adverse events associated with laboratory abnormalities, the event should be graded on the basis of the clinical severity in the context of the underlying conditions; this may or may not be in agreement with the grading of the laboratory abnormality.

The distinction between the seriousness and the severity of an adverse event should be noted. Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For example, a headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events.

For AEs associated with laboratory abnormalities, the event should be graded on the basis of the clinical severity in the context of the underlying conditions; this may or may not be in agreement with the grading of the laboratory abnormality.

### 7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead

Requirements for collection prior to study drug initiation:

After informed consent, but prior to initiation of study medication, the following types of events should be reported on the eCRF:

- all SAEs and adverse events related to protocol-mandated procedures.

### 7.3.1. Adverse Events

Following initiation of study medication, collect all AEs, regardless of cause or relationship, until 30-days after last administration of study IMP must be reported to the eCRF database as instructed.

All AEs should be followed up until resolution or until the adverse event is stable, if possible. Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up period.
7.3.2. **Serious Adverse Events**

All SAEs, regardless of cause or relationship, that occurs after the subject first consents to participate in the study (i.e, signing the informed consent) and throughout the duration of the study, including the protocol-required post treatment follow-up period, must be reported to the eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also includes any SAEs resulting from protocol-associated procedures performed after informed consent is signed.

Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the last dose of study IMP, regardless of causality, should also be reported.

Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; however, if the investigator learns of any SAEs that occur after study participation has concluded and the event is deemed relevant to the use of IMP, he/she should promptly document and report the event to Gilead DSPH.

**Electronic Serious Adverse Event (eSAE) Reporting Process**

- Site personnel record all SAE data in the eCRF database and from there transmit the SAE information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. Detailed instructions can be found in the eCRF completion guidelines.

- If it is not possible to record and submit the SAE information electronically, because the eCRF database cannot be accessed or is not available (including at study start), record the SAE on the paper serious adverse event report form and submit by e-mail or fax within 24 hours of the investigator’s knowledge of the event to:

  **Gilead DSPH contact information:**
  Email: Safety_FC@gilead.com
  Fax: +1 (650) 522-5477

- As soon as it is possible to do so, any SAE reported via paper must be transcribed into the eCRF Database according to instructions in the eCRF completion guidelines.

- If an SAE has been reported via a paper form because the eCRF database has been locked, no further action is necessary.

- All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the eCRF completion guideline.

- Additional information may be requested to ensure the timely completion of accurate safety reports.
• Any medications necessary for treatment of the SAE must be recorded onto the concomitant medication section of the subject’s CRF/eCRF and the event description section of the SAE form.

• For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other documents are also to be submitted by e-mail or fax when requested and applicable. Transmission of such documents should occur without personal subject identification, maintaining the traceability of a document to the subject identifiers.

7.4. Gilead Reporting Requirements

Depending on relevant local legislation or regulations, including the applicable US FDA Code of Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and other country-specific legislation or regulations, Gilead may be required to expedite to worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in current regulations.

Assessment of expectedness for SAEs will be determined by Gilead using reference safety information specified in the investigator’s brochure or relevant local label as applicable.

All investigators will receive a safety letter notifying them of relevant SUSAR reports associated with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as is practical, where this is required by local regulatory agencies, and in accordance with the local institutional policy.

7.5. Toxicity Management

All clinical and clinically significant laboratory toxicities will be managed according to uniform guidelines detailed in Appendix 3 as outlined below.

• Clinical events and clinically significant laboratory abnormalities will be graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 4).

• Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat testing within 3 calendar days of receipt of results and before investigational medicinal product discontinuation, unless such a delay is not consistent with good medical practice.

• Any questions regarding toxicity management should be directed to the Gilead Medical Monitor.

7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event

Continue study drug at the discretion of the Investigator.
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event

- For Grade 3 clinically significant laboratory abnormality or clinical event, investigational medicinal product may be continued if the event is considered to be unrelated to investigational medicinal product.

- For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by repeat testing, that is considered to be related to investigational medicinal product, investigational medicinal product will be withheld until the toxicity returns to Grade 2. When restarting investigational medicinal product following resolution of the adverse event, the investigational medicinal product should be restarted at full dose upon discussion with the Gilead Sciences Medical Monitor.

- If a laboratory abnormality recurs to Grade 3 following rechallenge with investigational medicinal product and is considered related to investigational medicinal product, then investigational medicinal product will be permanently discontinued and the subject managed according to local practice. Recurrence of laboratory abnormalities considered unrelated to investigational medicinal product may not require permanent discontinuation but requires discussion with the Gilead Sciences Medical Monitor.

7.5.3. Grade 4 Laboratory Abnormality or Clinical Event

- For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality confirmed by repeat testing that is considered related to investigational medicinal product, investigational medicinal product will be permanently discontinued and the subject managed according to local practice. The subject should be followed as clinically indicated until the laboratory abnormality returns to baseline or is otherwise explained, whichever occurs first. A clinically significant Grade 4 laboratory abnormality that is not confirmed by repeat testing should be managed according to the algorithm for the new toxicity grade.

- Investigational medicinal product may be continued without dose interruption for a clinically non-significant Grade 4 laboratory abnormality (eg, Grade 4 CK after strenuous exercise, or triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event considered unrelated to investigational medicinal product requires discussion with the Gilead Sciences Medical Monitor.

7.5.4. Management of Possible Abacavir Hypersensitivity Reaction

Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to increased risk of hypersensitivity reaction, unless no other therapeutic option is available based on the treatment history and resistance testing.

In a clinical study, 3.4% of subjects with a negative HLA-B*5701 status receiving abacavir developed a hypersensitivity reaction. Therefore, even in the absence of HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.
Hypersensitivity reactions are characterized by the appearance of symptoms indicating multi-organ system involvement. Almost all hypersensitivity reactions will have fever and/or rash as part of the syndrome. Other signs and symptoms may include respiratory signs and symptoms such as dyspnoea, sore throat, cough, and abnormal chest x-ray findings (predominantly infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, vomiting, diarrhea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequently observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia). The symptoms related to this hypersensitivity reaction worsen with continued therapy and can be life-threatening. These symptoms usually resolve upon discontinuation of abacavir.

Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of treatment with abacavir, although these reactions may occur at any time during therapy. Patients should be monitored closely, especially during the first two months of treatment with abacavir.

Regardless of their HLA-B*5701 status, patients who are diagnosed with a hypersensitivity reaction whilst on therapy MUST discontinue study drug immediately and MUST NEVER be restarted. Restarting study drug following a hypersensitivity reaction results in a prompt return of symptoms within hours. This recurrence is usually more severe than on initial presentation, and may include life-threatening hypotension and death. To avoid a delay in diagnosis and minimize the risk of a life-threatening hypersensitivity reaction, study drug must be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicinal products) {Ezzati et al 2003}.

### 7.5.5. Management of Potential Hepatobiliary Toxicity

Monkeys given a high dose (1000 mg/kg/day) for 39 weeks had evidence of biliary hyperplasia and hepatocyte hypertrophy on histopathologic examination. The risk to humans given the clinical dose of GS-9883 (50 mg/day) is unknown. Investigators should be aware of this potential toxicity. Any study subject exhibiting signs/symptoms or laboratory abnormalities suggestive of possible hepatobiliary toxicity should undergo thorough examination and clinical workup as deemed appropriate by the Investigator, and the Investigator must communicate promptly with the Gilead Medical Monitor. Consideration should be given to appropriate imaging studies (for example, ultrasound of the liver and biliary tree) and potential consultation with a gastroenterologist with specialty training in hepatobiliary diseases. Management of graded laboratory and clinical abnormalities will be managed as outlined in Section 7.5.

### 7.5.6. On-Treatment Hepatitis C Management

If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of the Investigator. Investigational medicinal product may be continued without dose interruption. Should the Investigator decide to initiate Hepatitis C treatment the Investigator must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected.
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to local medical practice for laboratory evaluations. If Hepatitis C treatment is initiated, Investigators should use the Gilead provided retest laboratory kits to manage the active Hepatitis C.

7.6. Special Situations Reports

7.6.1. Definitions of Special Situations

Special situation reports include all reports of medication error, abuse, misuse, overdose, reports of adverse events associated with product complaints, and pregnancy reports regardless of an associated AE.

Medication error is any unintentional error in the prescribing, dispensing, or administration of a medicinal product while in the control of the health care provider, subject, or consumer.

Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a subject.

Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in accordance with the protocol instructions or the local prescribing information.

An overdose is defined as an accidental or intentional administration of a quantity of a medicinal product given per administration or cumulatively which is above the maximum recommended dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in question). In cases of a discrepancy in drug accountability, overdose will be established only when it is clear that the subject has taken the excess dose(s). Overdose cannot be established when the subject cannot account for the discrepancy except in cases in which the investigator has reason to suspect that the subject has taken the additional dose(s).

Product complaint is defined as complaints arising from potential deviations in the manufacture, packaging, or distribution of the medicinal product.

7.6.2. Instructions for Reporting Special Situations

7.6.2.1. Instructions for Reporting Pregnancies

The investigator should report pregnancies in female study subjects that are identified after initiation of study medication and throughout the study, including the post study drug follow-up period, to the Gilead DSPH using the pregnancy report form within 24 hours of becoming aware of the pregnancy.

Refer to below and the eCRF completion guidelines for full instructions on the mechanism of pregnancy reporting.

The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a pregnancy without medical reasons.
Any premature termination of pregnancy (e.g., a spontaneous abortion, an induced therapeutic abortion due to complications or other medical reasons) must be reported within 24 hours as an SAE. The underlying medical reason for this procedure should be recorded as the AE term.

A spontaneous abortion is always considered to be an SAE and will be reported as described in Section 7.3. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must be reported to Gilead DSPH.

The subject should receive appropriate monitoring and care until the conclusion of the pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report form. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows: Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477.

Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs must also be reported and relevant information should be submitted to Gilead DSPH using the pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gilead DSPH, fax number +1 650 522-5477 or email Safety_FC@gilead.com.

Refer to Appendix 6 for Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements.

7.6.2.2. Reporting Other Special Situations

All other special situation reports must be reported on the special situations report form and forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. These reports must consist of situations that involve study IMP and/or Gilead concomitant medications, but do not apply to non-Gilead concomitant medications.

Special situations involving non-Gilead concomitant medications does not need to be reported on the special situations report form; however, for special situations that result in AEs due to a non-Gilead concomitant medication, the AE should be reported on the AE form.

Any inappropriate use of concomitant medications prohibited by this protocol should not be reported as “misuse,” but may be more appropriately documented as a protocol deviation.

Refer to Section 7.3.2 and the eCRF completion guidelines for full instructions on the mechanism of special situations reporting.

All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and signs, clinical management, and outcome will be reported, when available.
8. STATISTICAL CONSIDERATIONS

8.1. Analysis Objectives and Endpoints

8.1.1. Analysis Objectives

The primary objective of this study is to evaluate the efficacy of a FDC of GS-9883/F/TAF versus a FDC of ABC/DTG/3TC in HIV-1 infected, antiretroviral treatment naïve-adult subjects as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 48.

The secondary objectives of this study are:

- To evaluate the efficacy, safety and tolerability of the two treatment groups through Weeks 48 and 96.
- To evaluate the bone safety of the two treatment groups as determined by the percentage change from baseline in hip and spine BMD through Weeks 48 and 96.

8.1.2. Primary Endpoint

The primary endpoint is the proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm.

8.1.3. Secondary Endpoint

The secondary endpoints include:

- The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 as defined by the US FDA-defined snapshot algorithm.
- The proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 as defined by the US FDA-defined snapshot algorithm.
- The change from baseline in log_{10} HIV-1 RNA and CD4+ cell count at Weeks 48 and 96.
- The percentage change from baseline in hip and spine BMD at Weeks 48 and 96.

8.2. Analysis Conventions

8.2.1. Analysis Sets

8.2.1.1. All Randomized

The randomized analysis set includes all subjects who are randomized into the study. This is the primary analysis set for by-subject listings.
8.2.1.2. Efficacy

8.2.1.2.1. Full Analysis Set (FAS)

The primary analysis set for efficacy analyses is defined as full analysis set (FAS), which will include all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study drug. Subjects will be grouped according to the treatment to which they were randomized.

8.2.1.2.2. Per-Protocol (PP) Analysis Set

The secondary analysis set for efficacy analyses is defined as per-protocol (PP) analysis set, which will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of study drug, and (3) have not committed any major protocol violation, including the violation of key entry criteria. Subjects will be grouped according to the treatment they actually received.

Subjects meeting any of the following criteria will be excluded from the Week 48 PP analysis set:

- Subjects who do not have on-treatment HIV-1 RNA in the Week 48 analysis window, except when missing is due to discontinuation of study drug for lack of efficacy.
- Subjects who do not meet the inclusion criterion that the screening genotype report must show sensitivity to FTC, TFV, ABC, and 3TC.
- Subjects who meet the exclusion criterion for receiving ongoing therapy with any of the medications listed in the table in protocol Section 4.3 including drugs not to be used with GS-9883, FTC, TAF, ABC, 3TC, and DTG.
- Nonadherence to study drug: subjects with adherence rate for active study drug up to the Week 48 Visit below the 2.5th percentile

8.2.1.3. Safety

The primary analysis set for safety analyses is defined as safety analysis set, which will include all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study drug. All the data collected up to 30 days after subjects permanently discontinue their study drug will be included in the safety summaries, unless specified otherwise. Subjects will be grouped according to the treatment they actually received.

8.2.1.4. Pharmacokinetics

8.2.1.4.1. Pharmacokinetic (PK) Substudy Analysis Set

The primary analysis set for intensive PK analyses is defined as the PK substudy analysis set, which will include all subjects who (1) are randomized into the study, (2) enrolled into the PK Substudy, (3) have received at least 1 dose of study drug, and (4) have at least 1 nonmissing intensive PK concentration data for the analyte under evaluation reported by the PK lab.
8.2.1.4.2. Pharmacokinetic (PK) Analysis Set

The primary analysis set for general PK analyses is defined as the PK analysis set, which will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of study drug, and (3) have at least 1 nonmissing PK concentration data for the analyte under evaluation reported by the PK lab.

8.2.1.5. DXA

8.2.1.5.1. Hip DXA Analysis Set

The primary analysis set for hip BMD analyses is defined as the Hip DXA analysis set, which will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of study drug, and (3) have nonmissing baseline hip BMD value. Subjects will be grouped according to the treatment they actually received.

8.2.1.5.2. Spine DXA Analysis Set

The primary analysis set for spine BMD analyses is defined as the Spine DXA analysis set, which will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of study drug, and (3) have nonmissing baseline spine BMD value. Subjects will be grouped according to the treatment they actually received.

8.3. Data Handling Conventions

HIV-1 RNA results of ‘No HIV-1 RNA detected’ and “< 20 cp/mL HIV-1 RNA Detected” will be imputed as 19 copies/mL for analysis purpose. Logarithm (base 10) transformation will be applied to HIV-1 RNA levels for efficacy analysis.

Laboratory data that are continuous in nature but are less than the lower limit of quantitation or above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus or minus one significant digit, respectively (e.g., if the result of a continuous laboratory test is < 20, a value of 19 will be assigned).

Missing data can have an impact upon the interpretation of the trial data. In general, values for missing data will not be imputed. However, a missing pre-treatment laboratory result would be treated as normal (i.e., no toxicity grade) for the laboratory abnormality summary.

All available data for subjects that do not complete the study will be included in data listings.
8.4. **Demographic Data and Baseline Characteristics**

Demographic and baseline characteristics will be summarized using standard descriptive methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for continuous variables and frequency and percentages for categorical variables.

Demographic data will include sex, race, ethnicity, and age.

Baseline characteristics will include body weight, height, body mass index, eGFR, HIV-1 infection, and enrollment distribution by randomization stratum will be summarized.

For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel (CMH) test will be used to compare treatment groups. For continuous demographic and baseline characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.

8.5. **Efficacy Analysis**

8.5.1. **Primary Analysis**

The primary efficacy endpoint is the proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 48 as determined by the US FDA-defined snapshot algorithm. The primary analysis of the efficacy will be based on the FAS.

8.5.1.1. US FDA-defined Snapshot Algorithm

The analysis window at Week 48 is defined as from Study Day 295 to Study Day 378, inclusive. All HIV-1 RNA data collected on-treatment (ie, including data collected up to 1 day after the last dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be defined as the following categories:

- **HIV-1 RNA < 50 copies/mL:** this includes subjects who have the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window

- **HIV-1 RNA ≥ 50 copies/mL:** this includes subjects
  
  a) Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or

  b) Who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window and
    
    1) Who discontinue study drug prior to or in the Week 48 analysis window due to lack of efficacy, or

    2) Who discontinue study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL
• No Virologic Data in the Week 48 analysis window: this includes subjects who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window because of the following:
  
  a) Discontinuation of study drug prior to or in the Week 48 analysis window due to AE or death (regardless of whether the last available on-treatment HIV-1 RNA < 50 copies/mL or not) or,
  
  b) Discontinuation of study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and the last available on-treatment HIV-1 RNA < 50 copies/mL or,
  
  c) Missing data during the window but on study drug.

8.5.1.2. Analysis of Primary Efficacy Endpoint

The null hypothesis is that the proportion of subjects achieving HIV-1 RNA < 50 copies/mL (as defined by the US FDA-defined snapshot algorithm) at Week 48 in GS-9883/F/TAF is at least 12% lower than the response rate in ABC/DTG/3TC; the alternative hypothesis is that the response rate in GS-9883/F/TAF is less than 12% lower than that in ABC/DTG/3TC.

Non-inferiority will be assessed using the conventional confidence interval approach. The point estimate of treatment difference (GS-9883/F/TAF – ABC/DTG/3TC) and the associated 2-sided 95% confidence interval will be constructed using a normal approximation method based on stratified Mantel-Haenszel proportions, where stratification factors include baseline HIV-1 RNA level (≤ 100,000 copies/mL vs. > 100,000 copies/mL) and region (US vs. Ex-US). Note that to avoid small or missing cells in analysis strata, CD4+ cell count is not stratified in analysis because HIV-1 RNA and CD4+ cell count are highly correlated.

It will be concluded that GS-9883/F/TAF is non-inferior to ABC/DTG/3TC if the lower bound of the 2-sided 95% CI of the difference (GS-9883/F/TAF – ABC/DTG/3TC) in the response rate is greater than -12%.

If non-inferiority of GS-9883/F/TAF to ABC/DTG/3TC is established, the lower bound of the 95% CI will be compared to 0; if the lower bound of the 95% CI is greater than 0, then superiority of GS-9883/F/TAF over ABC/DTG/3TC will be established.

8.5.2. Secondary Analyses

The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 and the proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and 96, as defined by the US FDA-defined snapshot algorithm, will be analyzed using the same method as for the primary efficacy endpoint.

The changes from baseline in log_{10} HIV-1 RNA and CD4+ cell count at Weeks 48 and 96 will be summarized by treatment using descriptive statistics. The differences in changes from baseline in log_{10} HIV-1 RNA and CD4+ cell count between 2 treatment groups and the associated
95% confidence intervals will be constructed using ANOVA models, including treatment (GS-9883/F/TAF vs. ABC/DTG/3TC), baseline HIV-1 RNA level ($\leq$ 100,000 copies/mL vs. > 100,000 copies/mL), and region (US vs. Ex-US) as fixed effects in the model.

In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward (LOCF) method and analyzed similarly.

### 8.6. Safety Analysis

All safety analyses will be performed using the safety analysis set.

All safety data collected on or after the date that the study drug was first administered up to the date of the last dose of study drug plus 30 days, unless specified otherwise will be summarized for subjects in the safety analysis set according to the study drug received.

Data for the pretreatment period and the period post the date of last dose of study drug plus 30 days will be included in data listings for all enrolled subjects.

#### 8.6.1. Extent of Exposure

A subject’s extent of exposure to study drug will be generated from the study drug administration page in eCRF. Exposure data will be summarized by treatment.

Duration of exposure to study drug will be expressed as the number of weeks between the first and last dose of the study drug, inclusive, regardless of temporary interruptions in study drug administration and summarized by treatment.

Dosing information for individual subjects will be listed.

#### 8.6.2. Adverse Events

Clinical and laboratory adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to the clinical database.

Events will be summarized on the basis of the date of onset for the event. A treatment-emergent adverse event will be defined as any adverse event with onset date on or after the study drug start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.

Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC, HLT [if applicable], and PT) will be provided by treatment. Additional summaries will include summaries for adverse events by grade, Investigator’s assessment of relationship to study drug, and effect on study drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of Stage 3 Opportunistic Illnesses in HIV are indicative of an AIDS-Defining Diagnoses. The Gilead medical personnel will review the possible Stage 3 events and approve the events that meet the definition. Those events that do meet the Stage 3 Opportunistic Illness definition of an AIDS-Defining Diagnosis will be listed.

A listing of Stage 3 Opportunistic Illnesses in HIV, can be found in Appendix 5.

8.6.3. Laboratory Evaluations

Selected laboratory data (using conventional units) will be summarized using only observed data. Absolute values and changes from baseline at all scheduled visits will be summarized.

Graded laboratory abnormalities will be defined using the grading scheme defined in Grading of laboratory abnormalities attached in Appendix 4.

Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days, will be summarized by treatment. If baseline data are missing, then any graded abnormality (i.e., at least a Grade 1) will be considered treatment emergent. The maximum post baseline toxicity grade will be summarized by laboratory parameter.

Laboratory abnormalities that occur before the first dose of study drug or after the last dose of study drug plus 30 days will be included in a data listing.

8.6.4. Bone Safety Evaluations

The percentage changes from baseline in hip/spine BMD at Weeks 48 and 96 will be summarized by treatment using descriptive statistics. The differences in percentage changes from baseline in hip/spine BMD between 2 treatment groups and the associated 95% confidence intervals will be constructed using ANOVA models, including treatment as a fixed effect in the model.

In addition, missing values for BMD will be imputed using LOCF method and analyzed similarly.

8.6.5. Other Safety Evaluations

Vital signs and safety ECG data will be summarized as appropriate.

8.7. Pharmacokinetic Analysis

For the intensive PK substudy, plasma concentrations of GS-9883 may be summarized by nominal sampling time using descriptive statistics. Pharmacokinetic parameters (C_{max}, T_{max}, C_{tau}, AUC_{tau}, and T_{1/2}, as appropriate) will be listed and summarized using descriptive statistics (eg, sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, minimum, and maximum). Plasma concentrations over time will be plotted in semi-logarithmic and linear formats as mean ± standard deviation, and median (Q1, Q3).
For the general PK analyses, the pharmacokinetics of GS-9883 may be evaluated using descriptive statistics or population approaches.

TAF and FTC concentrations may be analyzed and PK parameters summarized as applicable.

8.8. Biomarker Analysis

For each biomarker of inflammation, immune activation, platelet function and renal tubular function, the percentage change from baseline will be summarized by treatment and visit using descriptive statistics. Differences in percentage changes from baseline in each biomarker between the 2 treatment groups will be tested using a Wilcoxon rank sum test.

8.9. Patient Report Outcomes (PRO)

The PRO measures based on questionnaires (eg, SF-36 and HIV Distress Module) will be summarized by treatment and visit using descriptive statistics.

8.10. Sample Size

A total of approximately 600 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment groups (300 subjects per treatment group), achieves at least 95% power to detect a non-inferiority margin of 12% in Week 48 response rate (HIV-1 RNA < 50 copies/mL as defined by the US FDA-defined snapshot algorithm) difference between the 2 treatment groups. For the sample size and power computations, it is assumed that both treatment groups have a response rate of 91% (based on Gilead Studies GS-US-292-0104 and GS-US-292-0111), that the non-inferiority margin is 12%, and that the significance level of the test is at a one-sided 0.025 level.

8.11. Data Monitoring Committee

An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy, and safety data of this study while the study is ongoing. The committee will convene after the first 300 subjects enrolled have completed Week 12 of the study or prematurely discontinues from the study drug, as well as after all subjects have completed Week 24 of the study or prematurely discontinues from the study drug. However, Gilead will defer to the IDMC for any decision to convene earlier or more frequently. The IDMC will examine the safety results of the trial and also focus on logistical issues such as accrual, retention, quality of clinical and laboratory data, and implications of results of external studies. Blinding will be preserved during the conduct of the study and access to unblinded data will be limited to designated parties.

No formal stopping rules will be used by the IDMC for safety outcomes. Rather, a clinical assessment will be made to determine if the nature, frequency, and severity of adverse events associated with a study regimen warrant the early termination of the study in the best interest of the participants.

For each IDMC analysis performed prior to the analysis of the primary efficacy endpoint, an alpha penalty of 0.00001 will be applied for the primary analysis of the primary endpoint.
8.12. Analysis Schedule

The Weeks 48 and 96 analyses will be conducted after all subjects either complete their Week 48 and 96 visits or prematurely discontinue from the study drug, respectively. Final analysis will be performed after all subjects complete the study or prematurely discontinue from the study.
9. RESPONSIBILITIES

9.1. Investigator Responsibilities

9.1.1. Good Clinical Practice

The investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the study subject: These standards are consistent with the European Union Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.


The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, providing documentation of their financial interest or arrangements with Gilead, or proprietary interests in the investigational drug under study. This documentation must be provided prior to the investigator’s (and any subinvestigator’s) participation in the study. The investigator and subinvestigator agree to notify Gilead of any change in reportable interests during the study and for 1 year following completion of the study. Study completion is defined as the date when the last subject completes the protocol-defined activities.

9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) Review and Approval

The investigator (or sponsor as appropriate according to local regulations) will submit this protocol, informed consent form, and any accompanying material to be provided to the subject (such as advertisements, subject information sheets, or descriptions of the study used to obtain informed consent) to an IRB/IEC. The investigator will not begin any study subject activities until approval from the IRB/IEC has been documented and provided as a letter to the investigator.

Before implementation, the investigator will submit to and receive documented approval from the IRB/IEC any modifications made to the protocol or any accompanying material to be provided to the subject after initial IRB/IEC approval, with the exception of those necessary to reduce immediate risk to study subjects.

9.1.3. Informed Consent

The investigator is responsible for obtaining written informed consent from each individual participating in this study after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. The
investigator must use the most current IRB- or IEC-approved consent form for documenting written informed consent. Each informed consent (or assent as applicable) will be appropriately signed and dated by the subject or the subject’s legally authorized representative and the person conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or local requirements. The consent form will inform subjects about pharmacogenomic testing and sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.

9.1.4. Confidentiality

The investigator must assure that subjects’ anonymity will be strictly maintained and that their identities are protected from unauthorized parties. Only subject initials, date of birth, another unique identifier (as allowed by local law) and an identification code will be recorded on any form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must be labeled in such a way as to protect subject identity while allowing the results to be recorded to the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a screening log showing codes, names, and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.

The investigator agrees that all information received from Gilead, including but not limited to the investigator brochure, this protocol, eCRF, the IMP, and any other study information, remain the sole and exclusive property of Gilead during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent from Gilead. The investigator further agrees to take all reasonable precautions to prevent the disclosure by any employee or agent of the study site to any third party or otherwise into the public domain.

9.1.5. Study Files and Retention of Records

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents should be classified into at least the following two categories: (1) investigator’s study file, and (2) subject clinical source documents.

The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB or IEC and governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.

The required source data should include sequential notes containing at least the following information for each subject:

- Subject identification (name, date of birth, gender);
- Documentation that subject meets eligibility criteria, ie, history, physical examination, and confirmation of diagnosis (to support inclusion and exclusion criteria);
• Documentation of the reason(s) a consented subject is not enrolled

• Participation in study (including study number);

• Study discussed and date of informed consent;

• Dates of all visits;

• Documentation that protocol specific procedures were performed;

• Results of efficacy parameters, as required by the protocol;

• Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

• Record of all adverse events and other safety parameters (start and end date, and including causality and severity);

• Concomitant medication (including start and end date, dose if relevant; dose changes);

• Date of study completion and reason for early discontinuation, if it occurs.

All clinical study documents must be retained by the investigator until at least 2 years or according to local laws, whichever is longer, after the last approval of a marketing application in an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. Investigators may be required to retain documents longer if specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The investigator must notify Gilead before destroying any clinical study records.

Should the investigator wish to assign the study records to another party or move them to another location, Gilead must be notified in advance.

If the investigator cannot provide for this archiving requirement at the study site for any or all of the documents, special arrangements must be made between the investigator and Gilead to store these records securely away from the site so that they can be returned sealed to the investigator in case of an inspection. When source documents are required for the continued care of the subject, appropriate copies should be made for storage away from the site.

9.1.6. Case Report Forms

For each subject consented, an eCRF will be completed by an authorized study staff member whose training for this function is documented according to study procedures. eCRF should be completed on the day of the subject visit to enable the sponsor to perform central monitoring of safety data. The Eligibility Criteria eCRF should be completed only after all data related to eligibility have been received. Subsequent to data entry, a study monitor will perform source
data verification within the EDC system. Original entries as well as any changes to data fields will be stored in the audit trail of the system. Prior to database lock (or any interim time points as described in the clinical data management plan), the investigator will use his/her log in credentials to confirm that the forms have been reviewed, and that the entries accurately reflect the information in the source documents. The eCRF capture the data required per the protocol schedule of events and procedures. System-generated or manual queries will be issued to the investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, who routinely review the data for completeness, correctness, and consistency. The site coordinator is responsible for responding to the queries in a timely manner, within the system, either by confirming the data as correct or updating the original entry, and providing the reason for the update (e.g. data entry error). At the conclusion of the trial, Gilead will provide the site with a read-only archive copy of the data entered by that site. This archive must be stored in accordance with the records retention requirements outlined in Section 9.1.5.

9.1.7. Investigational Medicinal Product Accountability and Return

Gilead recommends that used and unused IMP supplies be returned to the shipping facility from which it came for eventual destruction. The study monitor will provide instructions for return. If return is not possible, the study monitor will evaluate each study center’s IMP disposal procedures and provide appropriate instruction for destruction of unused IMP supplies. If the site has an appropriate standard operating procedure (SOP) for drug destruction as determined by Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained for central files.

If IMP is destroyed on site, the investigator must maintain accurate records for all IMP destroyed. Records must show the identification and quantity of each unit destroyed, the method of destruction, and the person who disposed of the IMP. Upon study completion, copies of the IMP accountability records must be filed at the site. Another copy will be returned to Gilead.

The study monitor will review IMP supplies and associated records at periodic intervals.

9.1.8. Inspections

The investigator will make available all source documents and other records for this trial to Gilead’s appointed study monitors, to IRBs or IECs, or to regulatory authority or health authority inspectors.

9.1.9. Protocol Compliance

The investigator is responsible for ensuring the study is conducted in accordance with the procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities

9.2.1. Protocol Modifications

Protocol modifications, except those intended to reduce immediate risk to study subjects, may be made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC in accordance with local requirements and receive documented IRB or IEC approval before modifications can be implemented.

9.2.2. Study Report and Publications

A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead will ensure that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in certain cases.

Investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:

- the results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form or the study has been completed at all study sites for at least 2 years

The investigator will submit to Gilead any proposed publication or presentation along with the respective scientific journal or presentation forum at least 30 days before submission of the publication or presentation.

No such communication, presentation, or publication will include Gilead’s confidential information (see Section 9.1.4).

The investigator will comply with Gilead’s request to delete references to its confidential information (other than the study results) in any paper or presentation and agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary.

9.3. Joint Investigator/Sponsor Responsibilities

9.3.1. Payment Reporting

Investigators and their study staff may be asked to provide services performed under this protocol, e.g. attendance at Investigator's Meetings. If required under the applicable statutory and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel expenses or reimbursements, consulting fees, and any other transfer of value.
9.3.2. Access to Information for Monitoring

In accordance with regulations and guidelines, the study monitor must have direct access to the investigator’s source documentation in order to verify the accuracy of the data recorded in the eCRF.

The monitor is responsible for routine review of the eCRF at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any subject records needed to verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure that any problems detected through any type of monitoring (central, on site) are resolved.

9.3.3. Access to Information for Auditing or Inspections

Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the clinical study. If the investigator is notified of an inspection by a regulatory authority the investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to provide to representatives of a regulatory agency or Gilead access to records, facilities, and personnel for the effective conduct of any inspection or audit.

9.3.4. Study Discontinuation

Both the sponsor and the investigator reserve the right to terminate the study at any time. Should this be necessary, both parties will arrange discontinuation procedures and notify the appropriate regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator will assure that adequate consideration is given to the protection of the subjects’ interests.
10. REFERENCES


11. APPENDICES

Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table (Blinded Phase)
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements
Appendix 1. Investigator Signature Page

GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404

STUDY ACKNOWLEDGEMENT

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

GS-US-380-1489 Amendment 1, 19 February 2016

This protocol has been approved by Gilead Sciences, Inc. The following signature documents this approval.

Hal Martin, MD (Printed)
Author

2/19/16
Date

INVESTIGATOR STATEMENT

I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.

I will provide all study personnel under my supervision copies of the protocol and access to all information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they are fully informed about the drugs and the study.

Principal Investigator Name (Printed)  Signature

Date  Site Number

CONFIDENTIAL  Page 93  19 February 2016
## Appendix 2. Study Procedures Table (Blinded Phase)

<table>
<thead>
<tr>
<th>Study Procedures</th>
<th>Screening&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Day 1&lt;sup&gt;b&lt;/sup&gt;</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>48</th>
<th>60</th>
<th>72</th>
<th>84</th>
<th>96</th>
<th>Every 12 Weeks</th>
<th>Unblinding Visit</th>
<th>30-Day Follow-up&lt;sup&gt;g&lt;/sup&gt;</th>
<th>Early Study Drugs DC&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Complete/Symptom-Directed Physical Exam</strong></td>
<td><strong>X</strong></td>
<td><strong>X</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-Lead ECG (performed supine)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Questionnaires</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DXA scan (spine &amp; hip)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs (blood pressure, pulse, respiration rate, and temperature), including Weight</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Urine Pregnancy Test&lt;sup&gt;b&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Serum Pregnancy Test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemistry Profile&lt;sup&gt;l&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Metabolic Assessments&lt;sup&gt;j&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Study Procedures</td>
<td>Screening&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Day 1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>24</td>
<td>36</td>
<td>48</td>
<td>60</td>
<td>72</td>
<td>84</td>
<td>96</td>
<td>Every 12 Weeks</td>
<td>Unblinding Visit</td>
<td>30-Day Follow-up&lt;sup&gt;g&lt;/sup&gt;</td>
<td>Early Study Drugs DC&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Estimated Glomerular Filtration Rate</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology Profile&lt;sup&gt;k&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma HIV-1 RNA</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B*5701&lt;sup&gt;w&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4+ Cell Count</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaluations of inflammation and immune activation, platelet function and renal tubular function</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma &amp; Urine Storage Sample</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV and HCV Serology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-1 Genotype&lt;sup&gt;l&lt;/sup&gt;</td>
<td>X&lt;sup&gt;l&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-1 Genotype/Phenotype&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single PK Sample&lt;sup&gt;m&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trough PK Samples&lt;sup&gt;n&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional Whole blood/EDTA for HLA testing, UGT1A1 and biomarkers</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Study Procedures** | **Screening** | **Day 1** | **End of Week**<sup>a,r</sup> | **Post-Week 96**<sup>n,s</sup> | **Every 12 Weeks** | **Unblinding Visit** | **30-Day Follow-up**<sup>q</sup> | **Early Study Drugs DC**<sup>c</sup>  
---|---|---|---|---|---|---|---|---  
Randomization<sup>1</sup> |  |  |  |  |  |  |  |  
Provide subject dosing diary to subjects | X | X | X | X | X |  |  |  
Optional PK Substudy<sup>o</sup> | X | X | X | X | X | X | X | X  
Optional PBMC Substudy<sup>p</sup> | X | X | X | X | X | X | X | X  
Study Drug Dispensation | X<sup>b</sup> | X | X | X | X | X | X | X<sup>n</sup>  
Study Drug Accountability | X | X | X | X | X | X | X | X  

---

**Notes:**

- **End of Week:** Evaluations to be completed within 30 days prior to Day 1.
- **Day 1:** Initiation of the first dose of study drug to take place in-clinic following completion of study procedures at the Day 1 visit, with the exception of DXA.
- **Every 12 Weeks:** Symptom-directed physical examination as needed.
- **Unblinding Visit:** HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to the next scheduled visit or at the next scheduled study visit, for a HIV-1 RNA and HIV-1 genotype and phenotype (reverse transcriptase, protease, and integrase genotype and phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section 6.14.1 and Section 6.14.2).
- **30-Day Follow-up:** Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained.
- **Early Study Drugs Discontinuation:** DXA scans to be performed in all eligible subjects on study drug, except for those in Germany, prior to or within 24 hours of the Day 1 Visit, Weeks 24, 48, 96 (+10 days), and at Unblinding Visit (+10 days) and the ESDD visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit).
- **Chemistry profile:** Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
- **CBC with differential and platelet count.**
The Investigator must have received the results from the screening genotype report before proceeding with the Day 1 visit. Screening genotype report must show sensitivity to TFV, FTC, 3TC and ABC. If genotype results from a local laboratory obtained ≤ 90 days prior to screening visit date show sensitivity to these drugs, this genotype will be acceptable to fulfill this inclusion criterion in the event that the genotype obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed.

A single PK blood sample will be collected at any time pre or post-dose

A trough PK blood sample will be collected between 20-28 hours following the last dose. Following an observed dose, a single post dose blood sample will be collected between 1 and 4 hours post dose.

A PK substudy will be performed in a subset of subjects (n=30) at selected study sites. The pharmacokinetic substudy visit must occur at the Week 4 or Week 8 visits. The substudy will include intensive PK profiling in plasma

A PBMC substudy will be performed in a subset of subjects (n=50) at selected study sites. A PBMC sample will be collected at Day 1 and Weeks 36 and 84.

Only required for those subjects not enrolling in the open-label rollover extension or those subjects who permanently discontinue study drugs and do not continue in the study through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a ± 6 days window may be used.

Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days through to Week 96, unless otherwise specified. The visit window at Weeks 48 and 96 will be ± 6 weeks of the protocol-specified visit date.

After Week 96, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. Visit window of ± 6 days for study visits post Week 96.

To be performed every 24 weeks after Week 96 until Unblinding Visit.

Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover extension.

Randomization may be performed up to 3 days prior to the in-clinic Day 1 visit, provided that all screening procedures have been completed and subject eligibility has been confirmed.

The Investigator must have received a negative screening test for HLA-B*5701 allele before proceeding with the Day 1 visit. If HLA-B*5701 results are available from a local laboratory prior to screening, this report will be acceptable to fulfill this inclusion criterion in the event that the HLA-B*5701 result obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed.
Appendix 3. Management of Clinical and Laboratory Adverse Events

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>May continue dosing at the discretion of the investigator</td>
<td>Repeat lab to confirm toxicity grade</td>
<td>Repeat lab to confirm toxicity grade</td>
<td>If confirmed and possibly or probably related to investigational medicinal products:</td>
</tr>
<tr>
<td>If confirmed and possibly and/or probably related to investigational medicinal products:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Withhold investigational medicinal products until ≤ Grade 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Restart all investigational medicinal products at full dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Grade 3 or 4 recurrence that is confirmed and possibly or probably related to investigational medicinal products, discontinue all investigational medicinal products dosing permanently</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Grade 3 or 4 recurrence that is confirmed and unrelated to investigational medicinal products, dosing may continue at the discretion of the investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Grade 3 or 4 recurrence that is considered unrelated to investigational medicinal products, continue all investigational medicinal products at the same dose at the discretion of the investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities

### Antiviral Toxicity Grading Scale Version: 01 April 2015

**HEMATOLOGY**

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>8.5 to 10.0 g/dL</td>
<td>7.5 to &lt; 8.5 g/dL</td>
<td>6.5 to &lt; 7.5 g/dL</td>
</tr>
<tr>
<td>HIV POSITIVE</td>
<td>85 to 100 g/L</td>
<td>75 to &lt; 85 g/L</td>
<td>65 to &lt; 75 g/L</td>
</tr>
</tbody>
</table>

**HIV NEGATIVE**

| Adult and Pediatric ≥ 57 Days | 10.0 to 10.9 g/dL | 9.0 to < 10.0 g/dL | 7.0 to < 9.0 g/dL | < 7.0 g/dL |
| OR | 100 to 109 g/L | 90 to < 100 g/L | 70 to < 90 g/L | < 70 g/L |
| OR Any decrease from Baseline | 2.5 to < 3.5 g/dL | 2.5 to < 3.5 g/dL | 2.5 to < 3.5 g/dL | 2.5 to < 3.5 g/dL |
| ANY | 25 to < 35 g/L | 25 to < 35 g/L | 25 to < 35 g/L | 25 to < 35 g/L |

**Infant, 36–56 Days**

| (HIV POSITIVE OR NEGATIVE) | 8.5 to 9.4 g/dL | 7.0 to < 8.5 g/dL | 6.0 to < 7.0 g/dL | < 6.0 g/dL |
| | 85 to 94 g/L | 70 to < 85 g/L | 60 to < 70 g/L | < 60 g/L |

**Infant, 22–35 Days**

| (HIV POSITIVE OR NEGATIVE) | 9.5 to 10.5 g/dL | 8.0 to < 9.5 g/dL | 7.0 to < 8.0 g/dL | < 7.0 g/dL |
| | 95 to 105 g/L | 80 to < 95 g/L | 70 to < 80 g/L | < 70 g/L |

**Infant, 1–21 Days**

| (HIV POSITIVE OR NEGATIVE) | 12.0 to 13.0 g/dL | 10.0 to < 12.0 g/dL | 9.0 to < 10.0 g/dL | < 9.0 g/dL |
| | 120 to 130 g/L | 100 to < 120 g/L | 90 to < 100 g/L | < 90 g/L |

**Absolute Neutrophil Count (ANC)**

| Adult and Pediatric, ≥ 7 Months# | 1000 to 1300/mm³ | 750 to < 1000/mm³ | 500 to < 750/mm³ | < 500/mm³ |
| | 1.00 to 1.30 GI/L | 0.75 to < 1.00 GI/L | 0.50 to < 0.75 GI/L | < 0.50 GI/L |
### HEMATOLOGY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absolute CD4+ Count</strong></td>
<td>300 to 400/mm³ 300 to 400/μL</td>
<td>200 to &lt; 300/mm³ 200 to &lt; 300/μL</td>
<td>100 to &lt; 200/mm³ 100 to &lt; 200/μL</td>
<td>&lt; 100/mm³ &lt; 100/μL</td>
</tr>
<tr>
<td>HIV NEGATIVE ONLY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 13 Years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Absolute Lymphocyte Count</strong></td>
<td>600 to 650/mm³ 0.60 to 0.65 GI/L</td>
<td>500 to &lt; 600/mm³ 0.50 to &lt; 0.60 GI/L</td>
<td>350 to &lt; 500/mm³ 0.35 to &lt; 0.50 GI/L</td>
<td>&lt; 350/mm³ &lt; 0.35 GI/L</td>
</tr>
<tr>
<td>HIV NEGATIVE ONLY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 13 Years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platelets</strong></td>
<td>100,000 to &lt; 125,000/mm³ 100 to &lt; 125 GI/L</td>
<td>50,000 to &lt; 100,000/mm³ 50 to &lt; 100 GI/L</td>
<td>25,000 to &lt; 50,000/mm³ 25 to &lt; 50 GI/L</td>
<td>&lt; 25,000/mm³ &lt; 25 GI/L</td>
</tr>
<tr>
<td><strong>WBCs</strong></td>
<td>2000/mm³ to 2500/mm³ 2.00 GI/L to 2.50 GI/L</td>
<td>1,500 to &lt; 2,000/mm³ 1.50 to &lt; 2.00 GI/L</td>
<td>1000 to &lt; 1,500/mm³ 1.00 to &lt; 1.50 GI/L</td>
<td>&lt; 1000/mm³ &lt; 1.00 GI/L</td>
</tr>
<tr>
<td><strong>Hypofibrinogenemia</strong></td>
<td>100 to 200 mg/dL 1.00 to 2.00 g/L</td>
<td>75 to &lt; 100 mg/dL 0.75 to &lt; 1.00 g/L</td>
<td>50 to &lt; 75 mg/dL 0.50 to &lt; 0.75 g/L</td>
<td>&lt; 50 mg/dL &lt; 0.50 g/L</td>
</tr>
<tr>
<td><strong>Hyperfibrinogenemia</strong></td>
<td>&gt; ULN to 600 mg/dL &gt; ULN to 6.0 g/L</td>
<td>&gt; 600 mg/dL &gt; 6.0 g/L</td>
<td>— —</td>
<td>— —</td>
</tr>
<tr>
<td><strong>Fibrin Split Product</strong></td>
<td>20 to 40 μg/mL 20 to 40 mg/L</td>
<td>&gt; 40 to 50 μg/mL &gt; 40 to 50 mg/L</td>
<td>&gt; 50 to 60 μg/mL &gt; 50 to 60 mg/L</td>
<td>&gt; 60 μg/mL &gt; 60 mg/L</td>
</tr>
<tr>
<td><strong>Prothrombin Time (PT)</strong></td>
<td>&gt; 1.00 to 1.25 × ULN</td>
<td>&gt; 1.25 to 1.50 × ULN</td>
<td>&gt; 1.50 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td><strong>International Normalized Ratio of prothrombin time (INR)</strong></td>
<td>1.1 to 1.5 × ULN</td>
<td>&gt;1.5 to 2.0 × ULN</td>
<td>&gt;2.0 to 3.0 × ULN</td>
<td>&gt;3.0 × ULN</td>
</tr>
<tr>
<td><strong>Activated Partial Thromboplastin Time (APTT)</strong></td>
<td>&gt; 1.00 to 1.66 × ULN</td>
<td>&gt; 1.66 to 2.33 × ULN</td>
<td>&gt; 2.33 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td><strong>Methemoglobin</strong></td>
<td>5.0 to 10.0%</td>
<td>&gt; 10.0 to 15.0%</td>
<td>&gt; 15.0 to 20.0%</td>
<td>&gt; 20.0%</td>
</tr>
</tbody>
</table>

#An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading any result within the LLN and ULN a 0.
<table>
<thead>
<tr>
<th>CHEMISTRY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyponatremia</strong></td>
<td>130 to &lt;LLN mEq/L</td>
<td>125 to &lt; 130 mEq/L</td>
<td>121 to &lt; 125 mEq/L</td>
<td>&lt; 121 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 1 Year</td>
<td>&gt;ULN to 150 mEq/L</td>
<td>&gt; 150 to 154 mEq/L</td>
<td>&gt; 154 to 159 mEq/L</td>
<td>&gt; 159 mEq/L</td>
</tr>
<tr>
<td>Infant &lt;1 Year</td>
<td>3.0 to &lt;LLN mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
<td>&lt; 2.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>3.0 to &lt;LLN mmol/L</td>
<td>2.5 to &lt; 3.0 mmol/L</td>
<td>2.0 to &lt; 2.5 mmol/L</td>
<td>&lt; 2.0 mmol/L</td>
</tr>
<tr>
<td><strong>Hypernatremia</strong></td>
<td>&gt;ULN to 150 mEq/L</td>
<td>&gt; 150 to 154 mEq/L</td>
<td>&gt; 154 to 159 mEq/L</td>
<td>&gt; 159 mEq/L</td>
</tr>
<tr>
<td>Adolescents</td>
<td>&gt;ULN to 150 mmol/L</td>
<td>&gt; 150 to 154 mmol/L</td>
<td>&gt; 154 to 159 mmol/L</td>
<td>&gt; 159 mmol/L</td>
</tr>
<tr>
<td><strong>Hypokalemia</strong></td>
<td>3.0 to &lt;LLN mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
<td>&lt; 2.0 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 1 Year</td>
<td>3.0 to &lt;LLN mmol/L</td>
<td>2.5 to &lt; 3.0 mmol/L</td>
<td>2.0 to &lt; 2.5 mmol/L</td>
<td>&lt; 2.0 mmol/L</td>
</tr>
<tr>
<td>Infant &lt;1 Year</td>
<td>3.0 to 3.4 mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
<td>&lt; 2.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>3.0 to 3.4 mmol/L</td>
<td>2.5 to &lt;3.0 mmol/L</td>
<td>2.0 to &lt;2.5 mmol/L</td>
<td>&lt; 2.0 mmol/L</td>
</tr>
<tr>
<td><strong>Hyperkalemia</strong></td>
<td>5.6 to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
<td>&gt; 7.0 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 1 Year</td>
<td>5.6 to 6.0 mmol/L</td>
<td>&gt; 6.0 to 6.5 mmol/L</td>
<td>&gt; 6.5 to 7.0 mmol/L</td>
<td>&gt; 7.0 mmol/L</td>
</tr>
<tr>
<td>Infant &lt;1 Year</td>
<td>&gt;ULN to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
<td>&gt; 7.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 6.0 mmol/L</td>
<td>&gt; 6.0 to 6.5 mmol/L</td>
<td>&gt; 6.5 to 7.0 mmol/L</td>
<td>&gt; 7.0 mmol/L</td>
</tr>
<tr>
<td><strong>Hypoglycemia</strong></td>
<td>55 to 64 mg/dL</td>
<td>40 to &lt; 55 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
<td>&lt; 30 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 1 Month</td>
<td>3.03 to 3.58 mmol/L</td>
<td>2.20 to &lt; 3.03 mmol/L</td>
<td>1.64 to &lt; 2.20 mmol/L</td>
<td>&lt; 1.64 mmol/L</td>
</tr>
<tr>
<td>Infant, &lt; 1 Month</td>
<td>50 to 54 mg/dL</td>
<td>40 to &lt; 50 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
<td>&lt; 30 mg/dL</td>
</tr>
<tr>
<td></td>
<td>2.8 to 3.0 mmol/L</td>
<td>2.2 to &lt; 2.8 mmol/L</td>
<td>1.7 to &lt; 2.2 mmol/L</td>
<td>&lt; 1.7 mmol/L</td>
</tr>
<tr>
<td>CHEMISTRY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Hyperglycemia, Nonfasting</td>
<td>116 to 160 mg/dL</td>
<td>&gt; 160 to 250 mg/dL</td>
<td>&gt; 250 to 500 mg/dL</td>
<td>&gt; 500 mg/dL</td>
</tr>
<tr>
<td></td>
<td>6.42 to 8.91 mmol/L</td>
<td>&gt; 8.91 to 13.90 mmol/L</td>
<td>&gt; 13.90 to 27.79 mmol/L</td>
<td>&gt; 27.79 mmol/L</td>
</tr>
<tr>
<td>Hyperglycemia, Fasting</td>
<td>110 to 125 mg/dL</td>
<td>&gt;125 to 250 mg/dL</td>
<td>&gt;250 to 500 mg/dL</td>
<td>&gt;500 mg/dL</td>
</tr>
<tr>
<td></td>
<td>6.08 to 6.96 mmol/L</td>
<td>&gt;6.96 to 13.90 mmol/L</td>
<td>&gt;13.90 to 27.79 mmol/L</td>
<td>&gt;27.79 mmol/L</td>
</tr>
<tr>
<td>Hypocalcemia (corrected for albumin if appropriate*)</td>
<td>7.8 &lt;LLN mg/dL</td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>6.1 to &lt; 7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.94 to &lt;LLN mmol/L</td>
<td>1.74 to &lt; 1.94 mmol/L</td>
<td>1.51 to &lt; 1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td>Adult and Pediatric ≥2 Years</td>
<td>7.8 to 8.4 mg/dL</td>
<td>7.0 to &lt;7.8 mg/dL</td>
<td>6.1 to &lt;7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.94 to 2.10 mmol/L</td>
<td>1.74 to &lt;1.94 mmol/L</td>
<td>1.51 to &lt;1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td>Pediatric ≥7 days -2 Years</td>
<td>6.5 to 7.5 mg/dL</td>
<td>6.0 to &lt; 6.5 mg/dL</td>
<td>5.5 to &lt; 6.0 mg/dL</td>
<td>&lt; 5.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.61 to 1.88 mmol/L</td>
<td>1.49 to &lt; 1.61 mmol/L</td>
<td>1.36 to &lt; 1.49 mmol/L</td>
<td>&lt; 1.36 mmol/L</td>
</tr>
<tr>
<td>Infant, &lt; 7 Days</td>
<td>&gt;ULN to 11.5 mg/dL</td>
<td>&gt; 11.5 to 12.5 mg/dL</td>
<td>&gt; 12.5 to 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 2.88 mmol/L</td>
<td>&gt; 2.88 to 3.13 mmol/L</td>
<td>&gt; 3.13 to 3.38 mmol/L</td>
<td>&gt; 3.38 mmol/L</td>
</tr>
<tr>
<td>Hypercalcemia (corrected for albumin if appropriate*)</td>
<td>11.5 to 12.4 mg/dL</td>
<td>12.4 to 12.9 mg/dL</td>
<td>12.9 to 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>2.86 to 3.10 mmol/L</td>
<td>3.10 to 3.23 mmol/L</td>
<td>3.23 to 3.38 mmol/L</td>
<td>&gt; 3.38 mmol/L</td>
</tr>
<tr>
<td>Infant, &lt; 7 Days</td>
<td>3.0 mg/dL to &lt; LLN</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>2.0 to &lt; 2.5 mg/dL</td>
<td>&lt; 2.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.74 mmol/L to &lt; LLN</td>
<td>0.62 to &lt; 0.74 mmol/L</td>
<td>0.49 to &lt; 0.62 mmol/L</td>
<td>&lt; 0.49 mmol/L</td>
</tr>
</tbody>
</table>

Hypocalcemia (ionized)
<table>
<thead>
<tr>
<th>CHEMISTRY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercalcemia (ionized)</td>
<td>&gt; ULN to 6.0 mg/dL</td>
<td>&gt; 6.0 to 6.5 mg/dL</td>
<td>&gt; 6.5 to 7.0 mg/dL</td>
<td>&gt; 7.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 1.50 mmol/L</td>
<td>&gt; 1.50 to 1.63 mmol/L</td>
<td>&gt; 1.63 to 1.75 mmol/L</td>
<td>&gt; 1.75 mmol/L</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>1.40 to &lt; LLN mg/dL</td>
<td>1.04 to &lt; 1.40 mg/dL</td>
<td>0.67 to &lt; 1.04 mg/dL</td>
<td>&lt; 0.67 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.2 to &lt; LLN mEq/L</td>
<td>0.9 to &lt; 1.2 mEq/L</td>
<td>0.6 to &lt; 0.9 mEq/L</td>
<td>&lt; 0.6 mgEq/L</td>
</tr>
<tr>
<td></td>
<td>0.58 to &lt; LLN mmol/L</td>
<td>0.43 to &lt; 0.58 mmol/L</td>
<td>0.28 to &lt; 0.43 mmol/L</td>
<td>&lt; 0.28 mmol/L</td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>2.0 to &lt; LLN mg/dL</td>
<td>1.5 to &lt; 2.0 mg/dL</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>&lt; 1.0 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>0.63 to &lt; LLN mmol/L</td>
<td>0.47 to &lt; 0.63 mmol/L</td>
<td>0.31 to &lt; 0.47 mmol/L</td>
<td>&lt; 0.31 mmol/L</td>
</tr>
<tr>
<td>&gt; 14 Years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pediatric 1 Year–14 Years</td>
<td>3.0 to &lt; LLN mg/dL</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.96 to &lt; LLN mmol/L</td>
<td>0.80 to &lt; 0.96 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td>Pediatric &lt; 1 Year</td>
<td>3.5 to &lt; LLN mg/dL</td>
<td>2.5 to &lt; 3.5 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.12 to &lt; LLN mmol/L</td>
<td>0.80 to &lt; 1.12 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.5 × ULN</td>
<td>&gt; 2.5 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 14 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infant, ≤ 14 Days (non-hemolytic)</td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 to 30.0 mg/dL</td>
<td>&gt; 30.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>342 to 428 μmol/L</td>
<td>&gt; 428 to 513 μmol/L</td>
<td>&gt; 513 μmol/L</td>
</tr>
<tr>
<td>Infant, ≤ 14 Days (hemolytic)</td>
<td>NA</td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>342 to 428 μmol/L</td>
<td>&gt; 428 μmol/L</td>
</tr>
</tbody>
</table>
### CHEMISTRY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Urea Nitrogen</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>Hyperuricemia</td>
<td>&gt; ULN to 10.0 mg/dL</td>
<td>&gt; 10.0 to 12.0 mg/dL</td>
<td>&gt; 12.0 to 15.0 mg/dL</td>
<td>&gt; 15.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 597 μmol/L</td>
<td>&gt; 597 to 716 μmol/L</td>
<td>&gt; 716 to 895 μmol/L</td>
<td>&gt; 895 μmol/L</td>
</tr>
<tr>
<td>Hyperuricemia</td>
<td>1.5 mg/dL to &lt; LLN</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>≥ 1 year</td>
<td>87 μmol/L to &lt; LLN</td>
<td>57 to &lt; 87 μmol/L</td>
<td>&lt; 27 μmol/L</td>
</tr>
<tr>
<td>Infant &lt; 1 Year</td>
<td>N/A</td>
<td>1.0 mg/dl to &lt; LLN</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>87 μmol/L to &lt; LLN</td>
<td>57 to &lt; 87 μmol/L</td>
<td>27 to &lt; 57 μmol/L</td>
<td>&lt; 27 μmol/L</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 10.0 mg/dL</td>
<td>&gt; 10.0 to 12.0 mg/dL</td>
<td>&gt; 12.0 to 15.0 mg/dL</td>
<td>&gt; 15.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 597 μmol/L</td>
<td>&gt; 597 to 716 μmol/L</td>
<td>&gt; 716 to 895 μmol/L</td>
<td>&gt; 895 μmol/L</td>
</tr>
<tr>
<td>Creatinine**</td>
<td>&gt; 1.50 to 2.00 mg/dL</td>
<td>&gt; 2.00 to 3.00 mg/dL</td>
<td>&gt; 3.00 to 6.00 mg/dL</td>
<td>&gt; 6.00 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; 133 to 177 μmol/L</td>
<td>&gt; 177 to 265 μmol/L</td>
<td>&gt; 265 to 530 μmol/L</td>
<td>&gt; 530 μmol/L</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>16.0 mEq/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mEq/L</td>
<td>8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>≥ 4 Years</td>
<td>16.0 mmol/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mmol/L</td>
<td>&lt; 8.0 mmol/L</td>
</tr>
<tr>
<td>Pediatric &lt; 4 Years</td>
<td>NA</td>
<td>11.0 mEq/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>11.0 mmol/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mmol/L</td>
<td>&lt; 8.0 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>NA</td>
<td>500 to 750 mg/dL</td>
<td>&gt; 750 to 1200 mg/dL</td>
<td>&gt; 1200 mg/dL</td>
</tr>
<tr>
<td>(Fasting)</td>
<td>5.64–8.47 mmol/L</td>
<td>&gt; 8.47–13.55 mmol/L</td>
<td>&gt; 13.55 mmol/L</td>
<td></td>
</tr>
<tr>
<td>LDL (Fasting)</td>
<td>130 to 160 mg/dL</td>
<td>&gt; 160 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td>Adult</td>
<td>3.35 to 4.15 mmol/L</td>
<td>&gt; 4.15 to 4.92 mmol/L</td>
<td>&gt; 4.92 mmol/L</td>
<td></td>
</tr>
<tr>
<td>LDL (Fasting)</td>
<td>110 to 130 mg/dL</td>
<td>&gt; 130 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td>NA</td>
</tr>
<tr>
<td>Pediatric &gt;2 to &lt;18 years</td>
<td>2.84 to 3.37 mmol/L</td>
<td>&gt; 3.37 to 4.92 mmol/L</td>
<td>&gt; 4.92 mmol/L</td>
<td></td>
</tr>
</tbody>
</table>
### CHEMISTRY

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercholesterolemia (Fasting)</td>
<td>200 to 239 mg/dL</td>
<td>&gt; 239 to 300 mg/dL</td>
<td>&gt; 300 mg/dL</td>
</tr>
<tr>
<td></td>
<td>5.16 to 6.19 mmol/L</td>
<td>&gt; 6.19 to 7.77 mmol/L</td>
<td>&gt; 7.77 mmol/L</td>
</tr>
<tr>
<td>Pediatric &lt; 18 Years</td>
<td>170 to 199 mg/dL</td>
<td>&gt; 199 to 300 mg/dL</td>
<td>&gt; 300 mg/dL</td>
</tr>
<tr>
<td></td>
<td>4.39 to 5.15 mmol/L</td>
<td>&gt; 5.15 to 7.77 mmol/L</td>
<td>&gt; 7.77 mmol/L</td>
</tr>
<tr>
<td>Creatine Kinase</td>
<td>3.0 to &lt; 6.0 × ULN</td>
<td>6.0 to &lt; 10.0 × ULN</td>
<td>10.0 to &lt; 20.0 × ULN</td>
</tr>
</tbody>
</table>

* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs. Please follow the Gilead convention of grading any result within the LLN and ULN a 0.

### ENZYMES

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (SGOT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
</tr>
<tr>
<td>GGT</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
</tr>
<tr>
<td>Total Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
</tr>
<tr>
<td>Pancreatic Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
</tr>
<tr>
<td>Lipase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 3.0 × ULN</td>
<td>&gt; 3.0 to 5.0 × ULN</td>
</tr>
<tr>
<td>Albumin Pediatric &lt;16 years</td>
<td>-</td>
<td>2.0 to &lt; LLN g/dL</td>
<td>&lt; 2.0 g/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 to &lt; LLN g/L</td>
<td>&lt; 20 g/L</td>
</tr>
<tr>
<td>≥ 16 years</td>
<td>3.0 g/dL to &lt; LLN</td>
<td>2.0 to &lt; 3.0 g/dL</td>
<td>&lt; 2.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>30 g/L to &lt; LLN</td>
<td>20 to &lt; 30 g/L</td>
<td>&lt; 20 g/L</td>
</tr>
</tbody>
</table>
## Urinalysis

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematuria (Dipstick)</strong></td>
<td>1+</td>
<td>2+</td>
<td>3–4+</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Hematuria (Quantitative)</strong></td>
<td>See Note below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>&gt;ULN - 10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td>Males</td>
<td>6-10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Proteinuria (Dipstick)</strong></td>
<td>1+</td>
<td>2–3+</td>
<td>4+</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Proteinuria, 24 Hour Collection</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 10 Years</td>
<td>200 to 999 mg/24 h</td>
<td>&gt;999 to 1999 mg/24 h</td>
<td>&gt;1999 to 3500 mg/24 h</td>
<td>&gt; 3500 mg/24 h</td>
</tr>
<tr>
<td>Pediatric &gt; 3 Mo to &lt; 10 Years</td>
<td>201 to 499 mg/m²/24 h</td>
<td>&gt;499 to 799 mg/m²/24 h</td>
<td>&gt;799 to 1000 mg/m²/24 h</td>
<td>&gt; 1000 mg/ m²/24 h</td>
</tr>
<tr>
<td><strong>Glycosuria (Dipstick)</strong></td>
<td>1+</td>
<td>2–3+</td>
<td>4+</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Notes:**
- Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to Dipstick Hematuria.
- With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
- If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for the AE.
<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac Arrhythmia (general) (By ECG or physical exam)</td>
<td>Asymptomatic AND No intervention indicated</td>
<td>Asymptomatic AND Non-urgent medical intervention indicated</td>
<td>Symptomatic, non-life-threatening AND Non-urgent medical intervention indicated</td>
<td>Life-threatening arrhythmia OR Urgent intervention indicated</td>
</tr>
<tr>
<td>Cardiac-ischemia/Infarction</td>
<td>NA</td>
<td>NA</td>
<td>Symptomatic ischemia (stable angina) OR Testing consistent with ischemia</td>
<td>Unstable angina OR Acute myocardial infarction</td>
</tr>
<tr>
<td>Hemorrhage (significant acute blood loss)</td>
<td>NA</td>
<td>Symptomatic AND No transfusion indicated</td>
<td>Symptomatic AND Transfusion of ≤ 2 units packed RBCs (for children ≤ 10 cc/kg) indicated</td>
<td>Life-threatening hypotension OR Transfusion of &gt; 2 units packed RBCs indicated (for children ≤ 10 cc/kg) indicated</td>
</tr>
<tr>
<td>Hypertension (with repeat testing at same visit)</td>
<td>140–159 mmHg systolic OR 90–99 mmHg diastolic</td>
<td>&gt; 159–179 mmHg systolic OR &gt; 99–109 mmHg diastolic</td>
<td>&gt; 179 mmHg systolic OR &gt; 109 mmHg diastolic</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization (other than ER visit) indicated Life-threatening consequences (eg, malignant hypertension) OR Hospitalization indicated (other than emergency room visit)</td>
</tr>
<tr>
<td>Pediatric ≤ 17 Years (with repeat testing at same visit)</td>
<td>NA</td>
<td>91st–94th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>≥ 95th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization indicated (other than emergency room visit)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>NA</td>
<td>Symptomatic, corrected with oral fluid replacement</td>
<td>Symptomatic, IV fluids indicated</td>
<td>Shock requiring use of vasopressors or mechanical assistance to maintain blood pressure</td>
</tr>
<tr>
<td>Pericardial Effusion</td>
<td>Asymptomatic, small effusion requiring no intervention</td>
<td>Asymptomatic, moderate or larger effusion requiring no intervention</td>
<td>Effusion with non-life-threatening physiologic consequences OR Effusion with nonurgent intervention indicated</td>
<td>Life-threatening consequences (eg, tamponade) OR Urgent intervention indicated</td>
</tr>
<tr>
<td>CARDIOVASCULAR</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Prolonged PR Interval</td>
<td>PR interval 0.21 to 0.25 sec</td>
<td>PR interval &gt; 0.25 sec</td>
<td>Type II 2nd degree AV block OR Ventricular pause &gt; 3.0 sec</td>
<td>Complete AV block</td>
</tr>
<tr>
<td>Pediatric ≤ 16 Years</td>
<td>1st degree AV block (PR &gt; normal for age and rate)</td>
<td>Type I 2nd degree AV block</td>
<td>Type II 2nd degree AV block</td>
<td>Complete AV block</td>
</tr>
<tr>
<td>Prolonged QTc</td>
<td>Asymptomatic, QTc interval 0.45 to 0.47 sec OR Increase interval &lt; 0.03 sec above baseline</td>
<td>Asymptomatic, QTc interval 0.48 to 0.49 sec OR Increase in interval 0.03 to 0.05 sec above baseline</td>
<td>Asymptomatic, QTc interval ≥ 0.50 sec OR Increase in interval ≥ 0.06 sec above baseline</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td>Pediatric ≤ 16 Years</td>
<td>Asymptomatic, QTc interval 0.450 to 0.464 sec</td>
<td>Asymptomatic, QTc interval 0.465 to 0.479 sec</td>
<td>Asymptomatic, QTc interval ≥ 0.480 sec</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td>Thrombosis/Embolism</td>
<td>NA</td>
<td>Deep vein thrombosis AND No intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Deep vein thrombosis AND Intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Embolic event (eg, pulmonary embolism, life-threatening thrombus)</td>
</tr>
<tr>
<td>Vasovagal Episode (associated with a procedure of any kind)</td>
<td>Present without loss of consciousness</td>
<td>Present with transient loss of consciousness</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Ventricular Dysfunction (congestive heart failure, CHF)</td>
<td>NA</td>
<td>Asymptomatic diagnostic finding AND intervention indicated</td>
<td>New onset with symptoms OR Worsening symptomatic CHF</td>
<td>Life-threatening CHF</td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Bronchospasm (acute)</td>
<td>FEV1 or peak flow reduced to 70% to 80%</td>
<td>FEV1 or peak flow 50% to 69%</td>
<td>FEV1 or peak flow 25% to 49%</td>
<td>Cyanosis OR FEV1 or peak flow &lt; 25% OR Intubation</td>
</tr>
<tr>
<td>Dyspnea or Respiratory Distress</td>
<td>Dyspnea on exertion with no or minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea on exertion causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities</td>
<td>Respiratory failure with ventilatory support indicated</td>
</tr>
<tr>
<td>Pediatric &lt; 14 Years</td>
<td>Wheezing OR minimal increase in respiratory rate for age</td>
<td>Nasal flaring OR Intercostal retractions OR Pulse oximetry 90% to 95%</td>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities OR Pulse oximetry &lt; 90%</td>
<td>Respiratory failure with ventilatory support indicated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OCULAR/VISUAL</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>Asymptomatic but detectable on exam</td>
<td>Symptomatic anterior uveitis OR Medical intervention indicated</td>
<td>Posterior or pan-uveitis OR Operative intervention indicated</td>
<td>Disabling visual loss in affected eye(s)</td>
</tr>
<tr>
<td>Visual Changes (from baseline)</td>
<td>Visual changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing inability to perform usual social &amp; functional activities</td>
<td>Disabling visual loss in affected eye(s)</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Thinning detectable by study participant or caregiver (for disabled adults)</td>
<td>Thinning or patchy hair loss detectable by health care provider</td>
<td>Complete hair loss</td>
<td>NA</td>
</tr>
<tr>
<td>Cutaneous Reaction – Rash</td>
<td>Localized macular rash</td>
<td>Diffuse macular, maculopapular, or morbilliform rash OR Target lesions</td>
<td>Diffuse macular, maculopapular, or morbilliform rash with vesicles or limited number of bullae OR Superficial ulcerations of mucous membrane limited to one site</td>
<td>Extensive or generalized bullous lesions OR Stevens-Johnson syndrome OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Toxic epidermal necrolysis (TEN)</td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hypopigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Pruritis (itching – no skin lesions) (See also Injection Site Reactions: Pruritis associated with injection)</td>
<td>Itching causing no or minimal interference with usual social &amp; functional activities</td>
<td>Itching causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Itching causing inability to perform usual social &amp; functional activities</td>
<td>NA</td>
</tr>
<tr>
<td>Condition</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>Anorexia</td>
<td>Loss of appetite without decreased oral intake</td>
<td>Loss of appetite associated with decreased oral intake without significant weight loss</td>
<td>Loss of appetite associated with significant weight loss</td>
<td>Life-threatening consequences OR Aggressive intervention indicated [eg, tube feeding or total parenteral nutrition]</td>
</tr>
<tr>
<td>Ascites</td>
<td>Asymptomatic</td>
<td>Symptomatic AND Intervention indicated (eg, diuretics or therapeutic paracentesis)</td>
<td>Symptomatic despite intervention</td>
<td>Life-threatening consequences</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>NA</td>
<td>Symptomatic AND Medical intervention indicated</td>
<td>Radiologic, endoscopic, or operative intervention indicated</td>
<td>Life-threatening consequences (eg, sepsis or perforation)</td>
</tr>
<tr>
<td>Constipation</td>
<td>NA</td>
<td>Persistent constipation requiring regular use of dietary modifications, laxatives, or enemas</td>
<td>Obstipation with manual evacuation indicated</td>
<td>Life-threatening consequences (eg, obstruction)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline/24 hr</td>
<td>Persistent episodes of unformed to watery stools OR Increase of 4–6 stools over baseline per 24 hrs.</td>
<td>Bloody diarrhea OR Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>Pediatric &lt; 1 Year</td>
<td>Liquid stools (more unformed than usual) but usual number of stools</td>
<td>Liquid stools with increased number of stools OR Mild dehydration</td>
<td>Liquid stools resulting in severe dehydration with aggressive rehydration indicated OR Hypotensive shock</td>
</tr>
<tr>
<td>Dysphagia-Odynophagia</td>
<td>Symptomatic but able to eat usual diet</td>
<td>Symptoms causing altered dietary intake without medical intervention indicated</td>
<td>Symptoms causing severely altered dietary intake with medical intervention indicated</td>
<td>Life-threatening reduction in oral intake</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td><strong>Mucositis/Stomatitis</strong>&lt;br&gt;(clinical exam)&lt;br&gt;See also Proctitis, Dysphagia-Odynophagia</td>
<td>Erythema of the mucosa</td>
<td>Patchy pseudomembranes or ulcerations</td>
<td>Confluent pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma</td>
<td>Tissue necrosis OR Diffuse spontaneous mucosal bleeding OR Life-threatening consequences (eg, aspiration, choking)</td>
</tr>
<tr>
<td><strong>Nausea</strong></td>
<td>Transient (&lt; 24 hours) or intermittent nausea with no or minimal interference with oral intake</td>
<td>Persistent nausea resulting in decreased oral intake for 24–48 hours</td>
<td>Persistent nausea resulting in minimal oral intake for &gt; 48 hours OR Aggressive rehydration indicated (eg, IV fluids)</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td><strong>Pancreatitis</strong></td>
<td>NA</td>
<td>Symptomatic AND Hospitalization not indicated (other than ER visit)</td>
<td>Symptomatic AND Hospitalization indicated (other than ER visit)</td>
<td>Life-threatening consequences (eg, sepsis, circulatory failure, hemorrhage)</td>
</tr>
<tr>
<td><strong>Proctitis</strong>&lt;br&gt;(functional-symptomatic)&lt;br&gt;Also see Mucositis/Stomatitis for Clinical Exam</td>
<td>Rectal discomfort AND No intervention indicated</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities OR Medical intervention indicated</td>
<td>Symptoms causing inability to perform usual social/functional activities OR Operative intervention indicated</td>
<td>Life-threatening consequences (eg, perforation)</td>
</tr>
<tr>
<td><strong>Vomiting</strong></td>
<td>Transient or intermittent vomiting with no or minimal interference with oral intake</td>
<td>Frequent episodes of vomiting with no or mild dehydration</td>
<td>Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated</td>
<td>Life-threatening consequences (eg, hypotensive shock)</td>
</tr>
<tr>
<td>Condition</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alteration in Personality- Behavior or in Mood (eg, agitation, anxiety, depression, mania, psychosis)</td>
<td>Alteration causing no or minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing inability to perform usual social &amp; functional activities</td>
<td>Behavior potentially harmful to self or others (eg, suicidal/homicidal ideation or attempt, acute psychosis) OR Causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Altered Mental Status For Dementia, see Cognitive and Behavioral/Attentional Disturbance (including dementia and ADD)</td>
<td>Changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Mild lethargy or somnolence causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Confusion, memory impairment, lethargy, or somnolence causing inability to perform usual social &amp; functional activities</td>
<td>Delirium OR obtundation, OR coma</td>
</tr>
<tr>
<td>Ataxia</td>
<td>Asymptomatic ataxia detectable on exam OR Minimal ataxia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing inability to perform usual social &amp; functional activities</td>
<td>Disabling ataxia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Cognitive and Behavioral/Attentional Disturbance (including dementia and Attention Deficit Disorder)</td>
<td>Disability causing no or minimal interference with usual social &amp; functional activities OR Specialized resources not indicated</td>
<td>Disability causing greater than minimal interference with usual social &amp; functional activities OR Specialized resources on part-time basis indicated</td>
<td>Disability causing inability to perform usual social &amp; functional activities OR Specialized resources on a full-time basis indicated</td>
<td>Disability causing inability to perform basic self-care functions OR Institutionalization indicated</td>
</tr>
<tr>
<td>CNS Ischemia (acute)</td>
<td>NA</td>
<td>NA</td>
<td>Transient ischemic attack</td>
<td>Cerebral vascular accident (CVA, stroke) with neurological deficit</td>
</tr>
<tr>
<td>Developmental delay – Pediatric ≤ 16 Years</td>
<td>Mild developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Moderate developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Severe developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Developmental regression, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
</tr>
<tr>
<td>Neurological Findings</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Headache</strong></td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform basic self-care functions OR Hospitalization indicated (other than ER visit) OR Headache with significant impairment of alertness or other neurologic function</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td>NA</td>
<td>Difficulty sleeping causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Difficulty sleeping causing inability to perform usual social &amp; functional activities</td>
<td>Disabling insomnia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td><strong>Neuromuscular Weakness</strong> (including myopathy &amp; neuropathy)</td>
<td>Asymptomatic with decreased strength on exam OR Minimal muscle weakness causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing inability to perform usual social &amp; functional activities</td>
<td>Disabling muscle weakness causing inability to perform basic self-care functions OR Respiratory muscle weakness impairing ventilation</td>
</tr>
<tr>
<td><strong>Neurosensory Alteration</strong> (including paresthesia and painful neuropathy)</td>
<td>Asymptomatic with sensory alteration on exam or minimal paresthesia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing inability to perform usual social &amp; functional activities</td>
<td>Disabling sensory alteration or paresthesia causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td><strong>Seizure: (new onset)</strong></td>
<td>NA</td>
<td>1 seizure</td>
<td>2–4 seizures</td>
<td>Seizures of any kind that are prolonged, repetitive (eg, status epilepticus), or difficult to control (eg, refractory epilepsy)</td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Seizure: (pre-existing)</td>
<td>NA</td>
<td>Increased frequency of pre-existing seizures (non-repetitive) without change in seizure character OR infrequent breakthrough seizures while on stable meds in a previously controlled seizure disorder</td>
<td>Change in seizure character from baseline either in duration or quality (eg, severity or focality)</td>
<td>Seizures of any kind that are prolonged, repetitive (eg, status epilepticus), or difficult to control (eg, refractory epilepsy)</td>
</tr>
<tr>
<td>For Worsening of Existing Epilepsy the Grades Should Be Based on an Increase from Previous Level of Control to Any of These Levels</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &lt; 5 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting 5–20 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &gt; 20 minutes</td>
<td>Seizure, generalized onset with or without secondary generalization, requiring intubation and sedation</td>
</tr>
<tr>
<td>– Pediatric &lt; 18 Years</td>
<td>NA</td>
<td>Present</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Syncope (not associated with a procedure)</td>
<td>NA</td>
<td>Present</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vertigo</td>
<td>Vertigo causing no or minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing inability to perform usual social &amp; functional activities</td>
<td>Disabling vertigo causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>Joint pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling joint pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>See also Arthritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>Stiffness or joint swelling causing no or minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing inability to perform usual social &amp; functional activities</td>
<td>Disabling joint stiffness or swelling causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>See also Arthralgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone Mineral Loss</td>
<td>BMD t-score or z-score –2.5 to –1.0</td>
<td>BMD t-score or z-score &lt; –2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
<td>Pathologic fracture causing life-threatening consequences</td>
</tr>
<tr>
<td>Pediatric &lt; 21 Years</td>
<td>BMD z-score –2.5 to –1.0</td>
<td>BMD z-score &lt; –2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
<td>Pathologic fracture causing life-threatening consequences</td>
</tr>
<tr>
<td>Myalgia (non-injection site)</td>
<td>Muscle pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling muscle pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>NA</td>
<td>Asymptomatic with radiographic findings AND No operative intervention indicated</td>
<td>Symptomatic bone pain with radiographic findings OR Operative intervention indicated</td>
<td>Disabling bone pain with radiographic findings causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Acute Systemic Allergic Reaction</td>
<td>Localized urticaria (wheals) with no medical intervention indicated</td>
<td>Localized urticaria with medical intervention indicated OR Mild angioedema with no medical intervention indicated</td>
<td>Generalized urticaria OR Angioedema with medical intervention indicated OR Symptomatic mild bronchospasm</td>
<td>Acute anaphylaxis OR Life-threatening bronchospasm OR laryngeal edema</td>
</tr>
<tr>
<td>Chills</td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>NA</td>
</tr>
<tr>
<td>Fatigue Malaise</td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>Incapacitating fatigue/malaise symptoms causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Fever (nonaxillary)</td>
<td>37.7°C to 38.6°C 99.8°F to 101.5°F</td>
<td>38.7°C to 39.3°C 101.6°F to 102.8°F</td>
<td>39.4°C to 40.5°C 102.9°F to 104.9°F</td>
<td>&gt; 40.5°C &gt; 104.9°F</td>
</tr>
<tr>
<td>Pain- Indicate Body Site See also Injection Site Pain, Headache, Arthralgia, and Myalgia</td>
<td>Pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling pain causing inability to perform basic self-care functions OR Hospitalization (other than ER visit) indicated</td>
</tr>
<tr>
<td>Unintentional Weight Loss</td>
<td>NA</td>
<td>5% to 9% loss in body weight from baseline</td>
<td>10% to 19% loss in body weight from baseline</td>
<td>≥ 20% loss in body weight from baseline OR Aggressive intervention indicated [eg, tube feeding or total parenteral nutrition]</td>
</tr>
</tbody>
</table>
### INJECTION SITE REACTION

<table>
<thead>
<tr>
<th>Injection Site Pain (pain without touching) Or Tenderness (pain when area is touched)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain/tenderness causing no or minimal limitation of use of limb</td>
<td>Pain/tenderness limiting use of limb OR Pain/tenderness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform basic self-care function OR Hospitalization (other than ER visit) indicated for management of pain/tenderness</td>
<td></td>
</tr>
</tbody>
</table>

| Injection Site Reaction (Localized), > 15 Years | Erythema OR Induration of 5 × 5 cm to 9 × 9 cm (or 25–81 × cm²) Erythema OR Induration OR Edema present but ≤ 2.5 cm diameter | Erythema OR Induration OR Edema > 9 cm any diameter (or > 81 cm²) Erythema OR Induration OR Edema > 2.5 cm diameter but < 50% surface area of the extremity segment (eg, upper arm/thigh) | Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage Erythema OR Induration OR Edema involving ≥ 50% surface area of the extremity segment (eg, upper arm/thigh) OR Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage | Necrosis (involving dermis and deeper tissue) Necrosis (involving dermis and deeper tissue) |

| Pediatric ≤ 15 Years | Erythema OR Induration OR Edema present but ≤ 2.5 cm diameter | Erythema OR Induration OR Edema > 9 cm any diameter (or > 81 cm²) Erythema OR Induration OR Edema > 2.5 cm diameter but < 50% surface area of the extremity segment (eg, upper arm/thigh) | Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage Erythema OR Induration OR Edema involving ≥ 50% surface area of the extremity segment (eg, upper arm/thigh) OR Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage | NA |

<p>| Pruritis Associated with Injection See also Skin: Pruritis (itching—no skin lesions) | Itching localized to injection site AND Relieved spontaneously or with &lt; 48 h treatment | Itching beyond the injection site but not generalized OR Itching localized to injection site requiring ≥ 48 h treatment | Generalized itching causing inability to perform usual social &amp; functional activities | NA |</p>
<table>
<thead>
<tr>
<th>ENDOCRINE/METABOLIC</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipodystrophy (eg, back of neck, breasts, abdomen)</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious changes on casual visual inspection</td>
<td>NA</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>NA</td>
<td>New onset without need to initiate medication OR Modification of current meds to regain glucose control</td>
<td>New onset with initiation of indicated med OR Diabetes uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, ketoacidosis, hyperosmolar non-ketotic coma)</td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious on casual visual inspection</td>
<td>NA</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>Asymptomatic</td>
<td>Symptomatic causing greater than minimal interference with usual social &amp; functional activities OR Thyroid suppression therapy indicated</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities OR Uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, thyroid storm)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Asymptomatic</td>
<td>Symptomatic causing greater than minimal interference with usual social &amp; functional activities OR Thyroid replacement therapy indicated</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities OR Uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, myxedema coma)</td>
</tr>
<tr>
<td>Lipoatrophy (eg, fat loss from the face, extremities, buttocks)</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious on casual visual inspection</td>
<td>NA</td>
</tr>
<tr>
<td>GENITOURINARY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Intermenstrual Bleeding (IMB)</td>
<td>Spotting observed by participant OR Minimal blood observed during clinical or colposcopic exam</td>
<td>Intermenstrual bleeding not greater in duration or amount than usual menstrual cycle</td>
<td>Intermenstrual bleeding greater in duration or amount than usual menstrual cycle</td>
<td>Hemorrhage with life-threatening hypotension OR Operative intervention indicated</td>
</tr>
<tr>
<td>Urinary Tract obstruction (eg, stone)</td>
<td>NA</td>
<td>Signs or symptoms of urinary tract obstruction without hydronephrosis or renal dysfunction</td>
<td>Signs or symptoms of urinary tract obstruction with hydronephrosis or renal dysfunction</td>
<td>Obstruction causing life-threatening consequences</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INFECTION</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection (any other than HIV infection)</td>
<td>Localized, no systemic antiμbial treatment indicated AND Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated OR Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated AND Symptoms causing inability to perform usual social &amp; functional activities OR Operative intervention (other than simple incision and drainage) indicated</td>
<td>Life-threatening consequences (eg, septic shock)</td>
</tr>
</tbody>
</table>

**Basic Self-care Functions:** Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.

**Usual Social & Functional Activities:** Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)

1. Candidiasis of bronchi, trachea, or lungs
2. Candidiasis of esophagus
3. Cervical cancer, invasive
4. Coccidioidomycosis, disseminated or extrapulmonary
5. Cryptococcosis, extrapulmonary
6. Cryptosporidiosis, chronic intestinal (> 1 month duration)
7. Cytomegalovirus disease (other than liver, spleen or nodes)
8. Cytomegalovirus retinitis (with loss of vision)
9. Encephalopathy, HIV-related
10. Herpes simplex: chronic ulcer(s) (> 1 month duration); or bronchitis, pneumonitis or esophagitis
11. Histoplasmosis, disseminated or extrapulmonary
12. Isosporiasis, chronic intestinal (> 1 month duration)
13. Kaposi’s sarcoma
14. Lymphoma, Burkitt’s (or equivalent term)
15. Lymphoma, immunoblastic (or equivalent term)
16. Lymphoma, primary, of brain
17. Mycobacterium avium complex or Myobacterium kansasii, disseminated or extrapulmonary
18. Mycobacterium tuberculosis, of any site, pulmonary, disseminated or extrapulmonary
19. Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
20. Pneumocystis jirovecii (previously known as “Pneumocystis carinii”) pneumonia
21. Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23. Salmonella septicemia, recurrent
24. Toxoplasmosis of brain
25. Wasting syndrome attributed to HIV infection

CDC Stage-3-Defining Opportunistic Illnesses in HIV Infection - 2014 {Schneider et al 2008}
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements

1) Definitions

a) Definition of Childbearing Potential

For the purposes of this study, a female born subject is considered of childbearing potential following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless permanently sterile or with medically documented ovarian failure.

Women are considered to be in a postmenopausal state when they are ≥ 54 years of age with cessation of previously occurring menses for ≥ 12 months without an alternative cause. In addition, women of any age with amenorrhea of ≥ 12 months may also be considered postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range and they are not using hormonal contraception or hormonal replacement therapy.

Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age.

b) Definition of Male Fertility

For the purposes of this study, a male born subject is considered of fertile after the initiation of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.

2) Contraception Requirements for Female Subjects

a) Study Drug Effects on Pregnancy and Hormonal Contraception

The data on GS-9883/F/TAF in pregnant women is limited or not available. There is no suspicion of human teratogenicity based on class effects or genotoxic potential. Relevant non-clinical reproductive studies for human pregnancy do not indicate a strong suspicion of human teratogenicity/fetotoxicity. Data from clinical pharmacokinetic interaction studies of GS-9883 and F/TAF have demonstrated that there is no reduction in the clinical efficacy of hormonal contraception or that the effect on hormonal contraception is insignificant. Please refer to the latest version of the GS-9883/F/TAF investigator’s brochure and the current Prescribing Information and local product labeling for ABC/DTG/3TC for additional information.

b) Contraception Requirements for Female Subjects of Childbearing Potential

The inclusion of female subjects of childbearing potential requires the use of highly effective contraceptive measures. They must have a negative serum pregnancy test at Screening and a negative pregnancy test on the Day 1 visit prior to randomization. At a minimum a pregnancy test will be performed at the end of relevant systemic exposure. In the event of a delayed menstrual period (over one month between menstruations), a pregnancy test must be performed to rule out pregnancy. This is true even for women of childbearing potential with infrequent or irregular periods. Female subjects must agree to one of the following from Screening until 30 days following the end of relevant systemic exposure.
• Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable method of contraception only when it is in line with the subject’s preferred and usual lifestyle.

Or

• Consistent and correct use of 1 of the following methods of birth control listed below.
  — Intrauterine device (IUD) with a failure rate of <1% per year
  — Intrauterine hormone-releasing system (IUS) with a failure rate of <1% per year
  — Tubal sterilization
  — Essure micro-insert system (provided confirmation of success 3 months after procedure)
  — Vasectomy in the male partner (provided that the partner is the sole sexual partner and had confirmation of surgical success 3 months after procedure)

Or

• Consistent and correct use of one hormonal method and one barrier method
  — Barrier methods
    ■ Diaphragm with spermicide
    ■ Cervical cap with spermicide
    ■ Male condom (with or without spermicide)
  — Hormonal methods
    ■ Oral contraceptives (either combined or progesterone only)
    ■ Injectable progesterone
    ■ Implants of levonorgestrel
    ■ Transdermal contraceptive patch
    ■ Contraceptive vaginal ring

Female subjects must also refrain from egg donation and in vitro fertilization during treatment and until at least 30 days after the end of relevant systemic exposure.
3) Contraception Requirements for Male Subjects

It is theoretically possible that a relevant systemic concentration may be achieved in a female partner from exposure of the male subject’s seminal fluid. Therefore, male subjects with female partners of childbearing potential must use condoms during treatment and until 90 days after the end of relevant systemic exposure. Additional contraception recommendations should also be considered if the female partner is not pregnant.

Male subjects must also refrain from sperm donation during treatment and until at least 90 days after the end of relevant systemic exposure.

4) Unacceptable Birth Control Methods

Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM). Female condom and male condom should not be used together.

5) Procedures to be Followed in the Event of Pregnancy

Subjects will be instructed to notify the investigator if they become pregnant at any time during the study, or if they become pregnant within 30 days of last study drug dose. Subjects who become pregnant or who suspect that they are pregnant during the study must report the information to the investigator and discontinue study drug immediately. Subjects whose partner has become pregnant or suspects she is pregnant during the study must report the information to the investigator. Instructions for reporting pregnancy, partner pregnancy, and pregnancy outcome are outlined in Section 7.3.